THE ROLE OF TELOMERIC RNA AT DYSFUNCTIONAL TELOMERES AND ITS IMPACT ON SENESCENCE AND AGING by J. AGUADO PEREZ
PhD degree in Systems Medicine (curriculum in Molecular Oncology) 
European School of Molecular Medicine (SEMM) 
University of Milan, Faculty of Medicine 
 
 
 
 
THE ROLE OF TELOMERIC RNA AT 
DYSFUNCTIONAL TELOMERES AND ITS IMPACT 
ON SENESCENCE AND AGING 
 
Julio Aguado Pérez 
IFOM, Milan 
Matricola n. R10800 
 
 
 
 
 
 
Supervisor   Dr. Fabrizio d’Adda di Fagagna 
    IFOM, Milan 
 
Internal co-supervisor Dr. Marco Foiani 
    IFOM, Milan 
 
External co-supervisor Dr. Joachim Lingner 
    EPFL, Lausanne 
 
Academic year 2017-2018 
 2 
  
 3 
 
 
 
 
 
 
 
 
 
 
Some Figures presented in this doctoral dissertation are already part of published reports.  
I have listed them below: 
 
Figures 13, 15, 16, 17, 18, 19, 20b-c, 21 and 22 are part of a report of Rossiello F, Aguado 
J, et al. in Nature Communications (Rossiello et al., 2017). 
 
Figures 7, 8, 9 and 10 are part of a report of Nguyen Q*, Aguado J* et al. in Nature 
Protocols (Nguyen et al., 2018). *Co-first authors.  
  
 4 
Table	of	Contents	
Table of Contents 4 
List of Abbreviations 7 
Figures Index 11 
Abstract 14 
1 INTRODUCTION 17 
1.1 The DNA damage response 18 
1.1.1 The DNA damage response pathway 18 
1.1.2 DNA double-strand break repair pathways 21 
1.2 The role of non-coding RNAs in DDR and DNA repair 25 
1.2.1 Non-coding RNAs 25 
1.2.2 The link between ncRNAs and DDR 25 
1.3 Telomeres: structures and functions 29 
1.3.1 The telomeric nucleoprotein structure and function 29 
1.3.2 Telomere length maintenance mechanisms 32 
1.3.3 The role of telomeres in immortality and cancer 34 
1.3.4 Transcription at telomeres 34 
1.4 Cellular senescence and Hutchinson-Gilford progeria syndrome 37 
1.4.1 Cellular senescence and aging 37 
1.4.2 Hutchinson-Gilford progeria syndrome 39 
2 Materials and methods 42 
2.1 Cell culture 43 
2.2 RNA isolation 44 
2.3 Real-time quantitative PCR for gene expression 44 
2.4 Real-time quantitative PCR for small RNAs 45 
2.5 Strand-specific real-time quantitative PCR 46 
 5 
2.6 Target-Enrichment of small RNAs (TEsR) 47 
2.7 Short interfering RNA transfection 48 
2.8 Transfection of Antisense oligonucleotides (ASOs) 49 
2.9 Retroviral transduction 50 
2.10 Protein immunoblotting 51 
2.11 Indirect immunofluorescence 52 
2.12 BrdU incorporation assay followed by immunofluorescence. 52 
2.13 Resazurin cell proliferation assay 53 
2.14 Ionizing radiation 53 
2.15 Imaging 54 
2.16 Antibodies 54 
2.17 Statistical analyses 55 
3 RESULTS 56 
3.1 Development of Target-Enrichment of small RNAs (TEsR). 57 
3.1.1 Overview and introduction of the method. 57 
3.1.2 Validation of the TEsR method. 60 
3.2 DICER and DROSHA-dependent telomeric RNAs are induced at dysfunctional 
telomeres. 64 
3.2.1 Telomere dysfunction induces the transcription of telomeric DDRNAs and their 
precursors. 64 
3.2.2 DDR at dysfunctional telomeres is DROSHA and DICER dependent. 70 
3.2.3 Telomeric antisense oligonucleotides prevent DDR activation at dysfunctional 
telomeres. 74 
3.3 A link between tDDRNAs and telomere-driven cellular senescence. 76 
3.3.1 Replicative senescent cells undergo telomeric DDRNA accumulation 76 
3.3.2 A role of tDDRNAs in IR-induced senescence 76 
3.4 The role of tDDRNAs at progerin-driven telomere dysfunction in Hutchinson–
Gilford Progeria Syndrome. 79 
 6 
3.4.1 Progerin expression induces the transcription of telomeric DDRNAs and their 
precursors. 79 
3.4.2 Progerin expression reduces cell proliferation and induces SASP expression. 80 
3.4.3 Telomeric antisense oligonucleotides reduce progerin-driven telomeric DNA damage 
and improve the proliferation of progerin-expressing cells. 81 
3.4.4 Human primary HGPS cells accumulate tDDRNAs and their inhibition improves 
their proliferation. 87 
3.4.5 tDDRNAs and tdilncRNAs accumulate in a progeric inducible skin mouse model. 90 
3.4.6 Progerin-expressing mice treated with telomeric antisense oligonucleotides live 
longer. 91 
4 DISCUSSION 94 
4.1 The role of telomere transcription induced by telomere dysfunction. 95 
4.1.1 A link between RNA and the DNA damage response. 95 
4.1.2 Telomere transcription upon telomere dysfunction. 96 
4.2 Implications of tDDRNAs inhibition in cellular senescence. 98 
4.3 Inhibition of progerin-driven telomere DDR signaling ameliorates the aging 
phenotype. 101 
4.4 Hutchinson-Gilford progeria syndrome: in search for a treatment. 104 
References 106 
Acknowledgements 120 
 
  
 7 
List	of	Abbreviations	
4OHT 4-hydroxytomaxifen 
53BP1 p53 binding protein 1 
a-NHEJ Alternative non-homologous end joining 
Ago2 Argonaute 2 
ALT Alternative lengthening of telomeres 
APB ALT-Associated PML Body 
aRNA Aberrant RNA 
ASO Antisense Oligonucleotide 
ATM Ataxia telangiectasia mutated 
ATM pS1981 Autophosphorylation of ATM at serine 1981 
ATR Ataxia telangiectasia and Rad3-related 
ATRIP ATR-interacting protein 
B2M Beta-2 microglobulin 
BRCA1 Breast cancer 1 
BrdU 5-bromodeoxyuridine 
c-NHEJ Classical non-homologous end joining 
CCF Cytoplasmic chromatin fragment 
CO-FISH Chromosome orientation fluorescence in situ hybridization 
CST CTC1-STN1-TEN1 complex 
DAPI 4'-6-Diamidino-2-phenylindole 
DDR DNA-damage response 
DDRNA DNA damage response RNA 
dilncRNA Damage-induced long non-coding RNA 
diRNA DSB-induced RNA 
 8 
DNA-PKcs DNA-PK catalytic subunit 
DSB DNA double-strand break 
ECTR Extrachromosomal telomeric repeat 
ER Estrogen receptor 
EZH2 Enhancer of Zeste Homolog 2 
FBS Fetal bovine serum 
FDA Food and Drug Administration 
FTI Farnesyltransferase inhibitor 
H3K9me3 Histone H3 trimethylated at lysine 9 
HBS HEPES-buffered saline 
HGPS Hutchinson–Gilford Progeria Syndrome 
HP1α Heterochromatin Protein 1 alpha 
HR Homologous recombination 
hTERT Human telomerase reverse transcriptase 
hTR Human telomerase RNA 
IL-1A Interleukin-1A 
IL-6 Interleukin-6 
IL-8 Interleukin-8 
IR Ionizing radiation 
KAT5 Lysine acetyl transferase 5 
LAP2α Lamina-associated polypeptide-a 
LNA Locked nucleic acid 
lncRNA Long non-coding RNA 
m7G 7-methylguanosine 
MDC1 Mediator of DNA damage checkpoint 1 
MEF Mouse embryonic fibroblast 
 9 
miRNA microRNA 
MRN Mre11-Rad50-Nbs1 complex 
NEAA Non-essential amino acid 
NF-kB Kappa-light-chain-enhancer of activated B cells 
NHEJ Non-homologous end joining 
nt nucleotide 
OB Oligonucleotide/oligosaccharide binding 
PARP1 Poly(ADP-ribose) polymerase 1 
PBS Phosphate Buffered Saline 
PFA Paraformaldehyde 
piRNA Piwi interacting RNA 
POT1 Protection of telomeres 1 
pRB Retinoblastoma protein 
RAP1 Repressor/activator protein 1 
RNA Pol II RNA Polymerase II 
RNAi RNA interference 
ROS Reactive oxygen species 
RPA Replication protein A 
Rplp0 Ribosomal protein large P0 
rRNA Ribosomal RNA 
RT Room temperature 
SA-β-gal Senescence-associated-β-galactosidase 
SAHF Senescence-associated heterochromatin foci 
SASP Senescence-associated secretory phenotype 
SDF Senescence-associated DNA-damage foci 
SDS Sodium dodecyl sulphate 
 10 
siRNA Small interfering RNA 
sncRNA Small non-coding RNA 
snoRNA Small nucleolar RNA 
snRNA Small nuclear RNA 
sRNA Small RNA 
SSB Single-strand break 
ssDNA Single-stranded DNA 
ssRNA Single-stranded RNA 
T-SCE Telomere-sister chromatid exchange 
TERRA Telomeric repeat-containing RNA 
TEsR Target-Enrichment of small RNAs 
TIF Telomere induced foci 
TIN2 TRF1-interacting nuclear factor 2 
TMM Telomere maintenance mechanism 
TopBP1 Topoisomerase II binding protein 1 
TRF1 Telomeric-repeat-binding factor 1 
TRF2 Telomeric-repeat-binding factor 2 
tRNA Transfer RNA 
tTR Tetracyclin-controlled transactivator 
TZAP Telomeric zinc finger-associated protein 
UV Ultraviolet light 
XRCC4 X-ray repair cross-complementing protein 4 
 
	 	
 11 
Figures	Index	
Figure 1. The DNA damage checkpoint response cascade. 19 
Figure 2. The major DNA repair pathways: NHEJ and HR. 22 
Figure 3. DNA Double-strand breaks (DSB) trigger the DNA damage checkpoint response 
cascade. 27 
Figure 4. The telomere structure: Shelterin complex and T-loop scheme. 29 
Figure 5. Consequences of progerin expression. 39 
Figure 6. Overview of the Targeted Enrichment of RNAs (TEsR) method. 58 
Figure 7. Profiles exemplifications for the monoadenylation of 3’ DNA linker and library 
and RNA bait generations. 59 
Figure 8. Bioanalyzer profiles and schematic overview of representative final TEsR 
libraries. 60 
Figure 9. Evaluation of the enrichment of three sRNA targets by TEsR. 62 
Figure 10. Assessing reproducibility and quantitativeness of the TEsR method. 63 
Figure 11. Induction of telomere dysfunction in Mouse Embryonic Fibroblasts (MEFs). 64 
Figure 12. Detection of DDRNAs: schematic description of the amplicon synthesis. 65 
Figure 13. Deprotection of telomeres leads to increased levels of tDDRNAs in MEFs. 66 
Figure 14. Induction of telomere dysfunction in T19 human cells. 67 
Figure 15. Deprotection of telomeres leads to increased levels of tDDRNAs in T19 cells. 68 
Figure 16. Characterization of tDDRNAs by Targeted Enrichment of RNAs (TEsR) 
method. 68 
Figure 17. Deprotection of telomeres leads to increased levels of tdilncRNAs in MEFs. 69 
 12 
Figure 18. Drosha and Dicer are involved in tDDRNA generation. 70 
Figure 19. Drosha and Dicer are involved in tdilncRNA processing. 71 
Figure 20. Drosha and Dicer are necessary for full DDR activation at deprotected 
telomeres. 73 
Figure 21. DROSHA and DICER are necessary for full DDR activation at deprotected 
telomeres in T19 cells. 74 
Figure 22. Telomeric ASOs inhibit DDR activation at dysfunctional telomeres. 75 
Figure 23. tDDRNAs are induced in replicative senescent cells. 76 
Figure 24. tDDRNAs accumulate in IR-induced senescent cells. 77 
Figure 25. Telomeric ASO treatment suppresses p21 and p16 induction of IR-induced cells 
while maintaining SASP gene expression levels. 78 
Figure 26. Progerin expression leads to increased levels of tDDRNAs. 79 
Figure 27. Progerin expression leads to increased levels of tdilncRNAs. 80 
Figure 28. Progerin expression reduces cell proliferation and induces SASP expression. 81 
Figure 29. Telomeric ASOs inhibit DDR activation at progerin-driven dysfunctional 
telomeres. 82 
Figure 30. Telomeric ASO treatment has no effect in non-telomeric DDR foci. 83 
Figure 31. Telomeric ASOs improve the proliferation of progerin-expressing cells. 84 
Figure 32. Lamin A and progerin protein levels remain unaltered upon telomeric ASO 
treatment. 85 
Figure 33. Unaltered proliferation rates in Lamin A-expressing cells upon ASO treatment.
 85 
 13 
Figure 34. SASP mRNA levels are unaltered upon ASO treatment upon progerin 
expression. 86 
Figure 35. Progerin-driven nuclear shape abnormalities are unaltered upon ASO treatment.
 87 
Figure 36. Telomeric ASO treatment improves proliferation rates by slowing down the 
growth decline of human primary HGPS fibroblasts. 88 
Figure 37. tDDRNA induction correlates with growth decline in human primary HGPS 
fibroblasts. 89 
Figure 38. Telomeric ASO treatment partially prevents the induction of p21 mRNA in 
primary HGPS cells 90 
Figure 39. Accumulation of tDDRNAs and tdilncRNAs in a progeric inducible skin mouse 
model. 91 
Figure 40. Progerin-expressing mice treated with telomeric ASOs live longer. 92 
Figure 41. dilncRNAs orchestrate the DDR by interacting with DDRNAs at DSBs. 95 
Figure 42. Model of progerin-driven telomere dysfunction: a major cause of growth 
decline. 102 
 
	 	
 14 
	
	
	
	
	
	
	
	
	
	
	
Abstract	
	 	
 15 
A novel class of small non-coding RNAs discovered in our laboratory, termed DNA 
damage response RNAs (DDRNAs), has been demonstrated to be locally generated upon 
DNA double strand break (DSB) induction, and to be necessary for full DNA Damage 
Response (DDR) activation (Francia et al., 2012, Francia et al., 2016). DDRNAs are 
generated following DSB induction upon transcription of the damaged locus and the 
synthesis of an RNA precursor further processed by the endoribonucleases DICER and 
DROSHA (Michelini et al., 2017). DSBs generated by different sources such as ionizing 
radiation, enzymatic DNA cleavage, or oncogene-induced replicative stress, induce the 
generation of DDRNAs (Francia et al., 2012).  
The aim of my PhD project was to investigate the mechanism underlying DDRNA-
dependent DDR activation specifically at telomeres, important chromosomal regions 
required for genomic stability that, if disrupted, are associated with aging-related diseases. 
In this dissertation, I show that telomere dysfunction, like DSBs, induces the transcription 
of telomeric DDRNAs and their precursors from both DNA strands of the telomere. Such 
transcripts are necessary for DDR activation and maintenance at dysfunctional telomeres. 
Most importantly, the use of sequence-specific antisense oligonucleotides (ASOs) allows 
the inhibition of telomere transcripts’ functions, thereby specifically inhibiting telomeric 
DDR. 
Furthermore, I show that telomere dysfunction in senescence, induced by either critically 
short telomeres or irreparable telomeres after ionizing radiation, induces the transcription 
of telomeric DDRNAs, whose inhibition leads to a decrease of the cyclin dependent kinase 
inhibitors p21 and p16. 
Telomere dysfunction is a key feature in Hutchinson–Gilford Progeria Syndrome (HGPS), 
and other premature aging syndromes. Hallmarks of HGPS are accumulation of DNA 
damage, chromosomal instability, and accelerated telomere shortening and dysfunction 
(Gonzalo et al., 2017). Here I show that progerin, a truncated form of the Lamin A protein 
whose expression causes HGPS, induces the transcription of telomeric DDRNAs and their 
 16 
precursors, both in vitro and in vivo. Furthermore, inhibition of progerin-driven telomere 
transcripts improves the growth potential of progerin-overexpressing and HGPS patient-
derived cells. Excitingly, this inhibition also increases the lifespan of an HGPS mouse 
model, opening the possibility for the use of this approach as a viable therapy to treat 
HGPS. 
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1.1 The DNA damage response 
Cell viability is threatened every time DNA lesions of any kind occur. Every human cell 
experiences tens of thousands of lesions per day (Lindahl and Barnes, 2000), which have 
the potential of blocking DNA replication and transcription and if unsuccessfully repaired 
can lead to mutations with serious consequences.  
Some alterations in DNA can originate through physiological processes like DNA 
replication, leading for instance to the introduction of DNA mismatches, or cell 
metabolism, which is responsible for the production of reactive oxygen species (ROS) 
derived from oxidative respiration, leading to oxidative DNA modifications (Valko et al., 
2006). 
Endogenously-produced ROS and nitrogen chemicals often lead to the formation of DNA 
single-strand breaks (SSBs) and, when two of them occur in close proximity, DNA double-
strand breaks (DSBs) can occur. DSBs can also be generated as a result of fork stalling 
following oncogene-induced replication stress (Di Micco et al., 2007). Importantly, 
although DSBs arise less frequently than the above-mentioned lesions, they are the most 
challenging lesions for the cell machinery to repair and can therefore be severely toxic 
(Khanna and Jackson, 2001).  
In addition to endogenous DNA damage sources, there are also several exogenous sources 
with the potential to compromise the integrity and stability of the genome. Some well-
studied sources are ultraviolet light (UV) (the most prevalent environmental DNA-
damaging agent causing approximately 100,000 lesions per exposed cell per hour), 
ionizing radiation (IR) and various genotoxic compounds (e.g. chemotherapics such as 
neocarzinostatin, bleomycin) (Ward, 1988, Iliakis et al., 2003, Povirk, 1996, Rastogi et al., 
2010).  
1.1.1 The DNA damage response pathway 
To handle the threats of DNA lesions, cells have developed mechanisms – known as DNA-
damage response (DDR) pathways – to detect DNA damage and amplify the signal of its 
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presence, and promote its repair (Harper and Elledge, 2007, Harrison and Haber, 2006, 
Polo and Jackson, 2011). When a DNA lesion arises, a DDR is activated, and cell-cycle 
progression is arrested in order to avoid the propagation of DNA alterations (known as the 
checkpoint function). Meanwhile, the cell coordinates a mechanism of DNA damage repair 
to maintain genome integrity.  
Exposed SSBs or DSBs induce the activation of a DDR (Figure 1). These two DNA 
lesions are sensed by complexes that recruit and activate the protein kinases ataxia 
telangiectasia and Rad3-related (ATR) or ataxia telangiectasia mutated (ATM), 
respectively, at sites of DNA damage (Shiloh, 2003, Bartek and Lukas, 2007).  
 
Adapted from (Sulli et al., 2012) 
Figure 1. The DNA damage checkpoint response cascade. 
DSBs are initially recognized by the Mre11-Rad50-Nbs1 (MRN) complex, while ssDNA is coated by RPA 
and the RAD9–RAD1–HUS1 (9-1-1) complex. These initial sensors allow the recruitment and activation of 
the apical kinases ATM and ATR, which in turn phosphorylate the histone variant H2AX at Ser139 (known 
as γH2AX) to recruit to the site of damage other DDR proteins such as MDC1, 53BP1 and BRCA1. The 
downstream kinases CHK2 and CHK1 are respectively phosphorylated by ATM and ATR, which ultimately 
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spread the signal to effector proteins such as p53 and CDC25. The three potential outcomes of the DDR are 
cell death by apoptosis or a checkpoint arrest, which can be successfully resolved by repair of the damaged 
site (leading to a resumption of cell proliferation) or enter a permanent arrest known as cellular senescence 
caused by persistent DNA damage. 
 
ATR and ATM are members of the family of phosphatidylinositol 3-kinase-like kinases, 
which tend to phosphorylate their substrates on a serine or threonine followed by 
glutamine: S/TQ motif (known as pS/TQ once phosphorylated) (Bensimon et al., 2010). 
The recruitment of ATR or ATM to DSBs induces the phosphorylation of the histone 
variant H2AX at serine 139 (so-called γH2AX). γH2AX serves for the retention of other 
DDR proteins at sites of DNA damage (Martin et al., 2009), which leads to a positive 
feedback loop that propagates γH2AX formation for megabases in cis along the chromatin 
(Iacovoni et al., 2010). Formation of γH2AX at the site of DNA breaks is cytologically 
detectable in the form of discrete bright foci when damaged cells are stained with 
antibodies against γH2AX or other DNA damage markers.  
When single-stranded DNA (ssDNA) is exposed, replication protein A (RPA) binds to it 
and serves as an initial signal for ATR-interacting protein (ATRIP) and ATR recruitment 
(Zou and Elledge, 2003, Ball et al., 2005), a process boosted by the recruitment of the 
RAD9–RAD1–HUS1 (9-1-1) complex and topoisomerase II binding protein 1 (TopBP1) to 
the chromatin where ssDNA sites arise, ultimately allowing the spreading of the DDR 
signalling (Cimprich and Cortez, 2008).  
ATM, in the absence of DSBs, remains inactive in the form of a homodimer (Shiloh and 
Ziv, 2013). However, when a DSB arises, it undergoes a conformational change leading to 
its monomerization that allows the specific recognition of chromatin flanking DSBs by 
interacting with the Mre11-Rad50-Nbs1 (MRN) complex. This interaction favours the 
acetylation of ATM by lysine acetyl transferase 5 (KAT5) (Sun et al., 2005), which in turn 
allows the full activation of ATM through its autophosphorylation at serine 1981 (ATM 
pS1981). Activated ATM then amplifies DDR signalling by phosphorylating (and 
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recruiting to the site of DNA break) the proteins mediator of DNA damage checkpoint 1 
(MDC1), p53 binding protein 1 (53BP1) and breast cancer 1 (BRCA1) (Bekker-Jensen et 
al., 2005, Stucki et al., 2005). 
It is known that ATR and ATM cross talk with each other to a certain extent. For instance, 
ATM favours the activation of ATR by enhancing DNA end resection (Jazayeri et al., 
2006). On the other hand, ATR is known to phosphorylate H2AX upon DNA replication 
stress induction, which may recruit and activate ATM to the chromatin where stressed 
replication forks are generated (Ward and Chen, 2001). 
Activation of ATR and ATM leads to the phosphorylation of the downstream protein 
kinases CHK1 and CHK2 respectively, although it has been reported that CHK1 can also 
be phosphorylated by ATM (Bekker-Jensen et al., 2006). Activated CHK1 and CHK2 
ultimately phosphorylate their respective targets CDC25 and p53 leading to cell death by 
apoptosis or activation of a checkpoint arrest. This proliferative arrest can be transient, in 
case the damaged genomic site is successfully repaired, or permanent, known as cellular 
senescence, where the DNA damaged site persists. 
1.1.2 DNA double-strand break repair pathways 
As DSBs are extremely toxic lesions, their successful repair is critical to maintain the 
integrity and stability of the genome and cell survival. Defects in the DNA repair pathways 
can lead to cell death or chromosomal rearrangements that have the potential of generating 
cancer. Cells have two major pathways to repair DSBs (Figure 2): homologous 
recombination (HR) and non-homologous end joining (NHEJ) (Chapman et al., 2012, 
Chang et al., 2017). 
NHEJ is a fast DNA repair pathway, where the rejoining of DNA ends is available 
throughout all phases of the cell cycle. ATM has been reported to contribute to NHEJ (Zha 
et al., 2011). When DSBs arise at DNA replication forks in the S phase of the cell cycle or 
after DNA replication in G2 phase, the second major DSB repair pathway, HR, is 
preferentially used (Karpenshif and Bernstein, 2012). As opposed to NHEJ, HR requires 
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both the homologous DNA as a repair template sequence (often from sister chromatids) 
and ssDNA ends to search for a homologous sequence. 
 
Adapted from (Brandsma and Gent, 2012) 
Figure 2. The major DNA repair pathways: NHEJ and HR. 
NHEJ: DNA ends are initially recognised by the KU70/80 heterodimer, which recruits and activates DNA-
PKcs and brings the nuclease Artemis to trim DNA ends. Next, the XRCC4-DNA Ligase IV-XLF complex 
seals the lesion. HR: DNA binding and resection is performed by the MRN-CtIP-complex to generate 
ssDNA, which is first coated by RPA and subsequently displaced by Rad51, a process mediated by BRCA2 
and RAD52. RAD51-loaded ssDNA allows the strand invasion on the homologous template leading to the 
formation of a D-loop that results in de novo DNA synthesis. 
NHEJ is the only repair pathway cells can use during G0, G1 and the early stages of S 
phase when homologous templates are yet not available (Lieber, 2010). The KU70/80 
heterodimeric complex binds to DNA ends, which allows the recruitment and 
autophosphorylation of DNA-PK catalytic subunit (DNA-PKcs) in a complex with the 
endonuclease Artemis (Goodarzi et al., 2006, Gu et al., 2010). If necessary, synthesis of de 
novo DNA in humans is carried out by two members of the POLX family, DNA 
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polymerase µ (Pol µ) and Pol λ (Moon et al., 2014), and DNA ligase IV associated with X-
ray repair cross-complementing protein 4 (XRCC4) and XLF, which stimulates DNA 
ligase IV enzyme activity (Grawunder et al., 1997), ligate the DNA ends.  
As HR uses a homologous DNA template for repair, it is generally restricted to the late S 
phase (after DNA replication takes place) and G2 phase of the cell cycle (Karpenshif and 
Bernstein, 2012). An early event in HR is the resection of the DSB in the 5'-to-3' direction, 
which generates 3’-ssDNA tails. The DNA-binding activity of the MRN complex and the 
exonuclease activity of its subunit NBS1, together with CtIP and BLM, promote this 
resection process that enables the strand invasion of the 3’ssDNA. ssDNA is coated by 
RPA, which controls its accessibility to the RAD51 recombinase (Morrical, 2015). A 
number of HR mediators, such as BRCA2 and RAD52, mediate the displacement of RPA 
to allow RAD51 to bind to ssDNA (Zelensky et al., 2014). RAD51-loaded ssDNA 
catalyses the invasion into a homologous DNA duplex to generate a displacement loop (D-
loop). Then, the ATP-dependent DNA translocase Rad54 allows the invading 3’DNA end 
to be extended by DNA polymerases to generate homologous DNA from the intact DNA 
duplex (Li and Heyer, 2009) and lastly DNA ligation takes place. This process often 
generates joint molecules, such as double Holliday junctions, which are generally 
dissolved by the RecQ helicases BLM and WRN proteins (Wu and Hickson, 2003) or by 
the MUS81-EME1 nuclease complex (Wyatt and West, 2014) to allow separation of the 
sister chromatids during mitosis.  
When, for various reasons, classical NHEJ (c-NHEJ) is impaired, an alternative 
mechanism called alternative NHEJ (a-NHEJ), also known as microhomology-mediated 
end joining and Pol θ-mediated end joining (Saito et al., 2016), is used. Given the 
extremely low frequency of human mutations in the NHEJ pathway, it is yet unclear 
whether a-NHEJ is an independent DNA repair pathway or whether its components usually 
serve other molecular pathways and only become relevant to DNA repair when NHEJ is 
compromised (Chang et al., 2017). Importantly, a-NHEJ is believed to require 
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microhomology DNA regions that range between 2 bp and 20 bp as opposed to the HR 
pathway, which usually requires longer lengths of DNA homology. The mechanisms of a-
NHEJ are yet unclear, however it is known to employ polymerase Pol θ (Wyatt et al., 
2016) and may also require the activity of poly(ADP-ribose) polymerase 1 (PARP1), CtIP, 
DNA ligase 3 and XRCC1 and the MRN complex (Sfeir and Symington, 2015). 
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1.2 The role of non-coding RNAs in DDR and DNA repair 
1.2.1 Non-coding RNAs 
Non-coding RNAs (ncRNA), which are defined as RNA molecules that are not translated 
into proteins, have been reported to exert a wide range of functions (St Laurent et al., 2015, 
Vickers et al., 2015). The growing list of the ncRNA landscape includes ribosomal RNAs 
(rRNAs), transfer RNAs (tRNAs), small nuclear RNAs (snRNAs), small nucleolar RNAs 
(snoRNAs), long non-coding RNAs (lncRNAs), microRNAs (miRNAs), small interfering 
RNAs (siRNAs) and piwi interacting RNAs (piRNAs). In addition to the above-mentioned 
well-established ncRNAs, increasing evidence supports the existence of a large variety of 
ncRNAs playing fundamental roles in diverse biological processes. Most studies are 
focused on the study of lncRNAs and just a small subset is focused on small RNAs 
(sRNAs). Among sRNA studies, most research so far has focused on miRNAs (Vickers et 
al., 2015). Since there is mounting evidence of sRNAs playing critical roles in cellular 
biology, new methods and sequencing techniques are needed to address the fundamental 
but challenging questions of: (i) whether or not (or in which biological context) sRNA 
exist; (ii) how many different sRNA isoforms there are and what are their lengths, 
sequences and quantities; (iii) what are the precursors of a mature sRNA; and (iv) what is 
the differential expression of low abundant sRNAs in different biological conditions.  
1.2.2 The link between ncRNAs and DDR 
In the recent years, strong evidence supports a conserved link between DNA damage and 
ncRNAs across species (d'Adda di Fagagna, 2014).  
In the plant Arabidopsis thaliana, small ncRNAs (sncRNAs), named DSB-induced RNAs 
(diRNAs), have been shown to orchestrate DNA repair by HR in a derived cell line where 
an inducible DSB was generated. These diRNAs are specifically induced upon DSB 
generation (Wei et al., 2012). They have the RNA sequence corresponding to the DNA-
damaged locus, are transcribed by RNA Polymerase IV, and their expression is dependent 
on the components of the RNA interference (RNAi) machinery Dicer-like proteins and 
 26 
Argonaute 2 (Ago2). Moreover, upon DSB generation, the expression of HR genes 
remains unaltered, which demonstrates a miRNA-independent mechanism (Wei et al., 
2012). 
In Drosophila melanogaster, transfection of a linearized plasmid has been reported to 
induce the generation of sncRNAs (21 nucleotides (nt)), which contain the corresponding 
DNA sequence of the transfected plasmid ends and are able to silence the transcription of 
the homologous DNA sequences (Michalik et al., 2012), and more recently have been 
demonstrated to be dispensable for DNA repair (Schmidts et al., 2016). Furthermore, in 
Neurospora crassa, sncRNAs termed qiRNAs (for QDE-2-interacting small RNAs) were 
reported to be transcribed from the rDNA locus in response to DNA damage (Lee et al., 
2009). Importantly, a single-stranded RNA (ssRNA) named aberrant RNA (aRNA) was 
reported to be required as precursor RNAs for qiRNA generation (Lee et al., 2010).  
Our laboratory has recently demonstrated, in line with the above-mentioned observations, 
the direct involvement of non-canonical sncRNAs in the modulation of the DDR in 
mammalian cells. Ionizing radiation, enzymatic DNA cleavage or oncogene-induced 
replicative stress induce the generation of DNA damage response RNAs (DDRNAs, 20-35 
nt), which are generated at DSBs and contain the sequence corresponding to the damaged 
genomic locus (Francia et al., 2012). The biogenesis of DDRNAs is dependent on the 
endoribonucleases DROSHA and DICER, and when either of them are inactivated, the 
formation of DDR foci containing upstream signalling proteins, such as ATM pS1981, 
53BP1 and MDC1, is impaired while γH2AX foci remain unaltered (Figure 3 and (Francia 
et al., 2012)). Recent additional evidence from our laboratory supports the notion that 
DDRNAs are dispensable for the direct recognition of DNA damage and H2AX 
phosphorylation, and are critical for the recruitment of DDR proteins downstream of 
γH2AX to form DDR foci at DSBs (Francia et al., 2016). Importantly, this effect is not 
observed upon depletion of GW182 proteins, effectors of the RNAi machinery, 
demonstrating a miRNA-independent mechanism.  
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Adapted from (d'Adda di Fagagna, 2014) 
Figure 3. DNA Double-strand breaks (DSB) trigger the DNA damage checkpoint response cascade. 
DNA ends are initially recognized by the MRN complex (MRE11-RAD50-NBS1) which recruits and 
activates the apical protein kinase ATM. Its activation promotes the phosphorylation of the histone variant 
H2AX on Ser139 (known as γH2AX). This process is sustained by the recruitment of other downstream 
mediators like 53BP1 and MDC1. Most importantly, a new class of small non-coding RNAs (ncRNAs), 
named DNA damage response RNAs (DDRNAs), has been shown to be transcribed upon DSB induction 
orchestrating events downstream γH2AX.  
In addition, more recent data from our laboratory indicates the existence of a longer 
precursor transcribed by RNA Polymerase II (RNA Pol II) from and towards the broken 
DNA ends upon DSB generation, which is then processed by DROSHA and DICER to 
generate DDRNAs (Michelini et al., 2017). In only apparent contrast, RNA Pol II-
dependent transcription in gene-coding genomic regions is known to be silenced upon 
DNA damage (Pankotai et al., 2012, Iannelli et al., 2017, Shanbhag et al., 2010). These 
apparently mutually exclusive scenarios can be reconciled by a unique hypothesis in 
which, upon DSB generation, the relaxation of chromatin surrounding the break allows the 
recruitment of apical DDR proteins and the RNA transcription machinery to the DSB. This 
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would subsequently favour the transcription and processing of DDRNA precursors 
allowing full activation of the DDR (Francia et al., 2012) ultimately leading to DNA 
damage-induced transcriptional silencing.  
Regarding DDRNA processing by DICER, in the recent years there has been increasing 
evidence of DICER nuclear localization (Ando et al., 2011, Ohrt et al., 2012, Gullerova 
and Proudfoot, 2012, Doyle et al., 2013), opposing the previous notion in which DICER 
was considered exclusively cytosolic (Billy et al., 2001, Provost et al., 2002), leaving open 
the possibility of a nuclear DICER DDRNA processing. Strongly supporting this 
hypothesis, a recent report has demonstrated that nuclear accumulation of a phosphorilated 
form of DICER localizes at DSBs in response to DNA damage (Burger et al., 2017). 
Lastly, upon DSB generation, proteins of the NHEJ pathway, such as Lig IV, XRCC4, 
KU-70, Pol μ and DNA-PK, have been reported to interact at DSBs with nascent RNAs 
located in actively transcribed genes (Chakraborty et al., 2016) a potential role of ncRNAs 
in favouring the recruitment of DDR factors. 
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1.3 Telomeres: structures and functions 
1.3.1 The telomeric nucleoprotein structure and function 
Telomeres are nucleoprotein structures at the ends of linear chromosomes (Figure 4). In 
humans and other vertebrates, telomeres are composed of a long DNA array of double-
stranded tandem TTAGGG repeats and associated telomeric DNA-binding proteins, the so-
called shelterin complex (de Lange, 2005).  
 
Adapted from (O'Sullivan and Karlseder, 2010) 
Figure 4. The telomere structure: Shelterin complex and T-loop scheme. 
Telomeres are nucleoprotein complexes composed of double-stranded TTAGGG DNA repeats (which extend 
for 5-10 kb in humans and up to 100 kb in rodents) and the shelterin proteins TRF1, TRF2, RAP1, TIN2, 
TPP1 and POT1. Telomeres contain a G-rich 3’ overhang which allows the formation of a t-loop structure by 
invading the upstream double-stranded TTAGGG repeats. This structure protects telomeres from being 
recognised as DSBs. 
Telomeres range from approximately 5-10 kb in human cells to 20-50 kb in mice, which 
can be synthesized by telomerase, a specialized reverse transcriptase (Greider, 1993). 
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Telomeres end with a single-stranded G-rich overhang, typically 50-300 nt long (Makarov 
et al., 1997, O'Sullivan and Karlseder, 2010). Apollo and Exo1 nucleases resect telomeric 
DNA in the 5’-3’ direction in order to generate the G-rich overhang (Wu et al., 2012), 
which is needed for the invasion of the double-stranded telomeric DNA leading to the 
formation of a specialized lasso-like structure called the telomere loop or t-loop (Griffith et 
al., 1999, Doksani et al., 2013).  
Telomeric DNA is associated with the shelterin complex (de Lange, 2005), a group of six 
proteins composed by: telomeric-repeat-binding factor 1 and 2 (TRF1 and TRF2), 
repressor/activator protein 1 (RAP1), TRF1-interacting nuclear factor 2 (TIN2), protection 
of telomeres 1 (POT1), and TPP1 (named after combining the first letter of each name, 
TINT1, PTOP and PIP1, given by the three laboratories that initially characterized it). 
TRF1 and TRF2 directly bind telomeric double-stranded DNA as homodimers through 
their MYB domain (Broccoli et al., 1997) and play a fundamental role in telomere 
protection and length regulation.  
TRF1 overexpression causes telomere shortening, while the expression of a dominant-
negative TRF1 leads to telomere lengthening (van Steensel and de Lange, 1997, Munoz et 
al., 2009). In mouse embryonic fibroblasts (MEFs), Trf1 deletion results in DNA 
replication fork stalling at telomeres leading to the formation of so-called fragile telomeres, 
which in turn cause DDR activation at the telomeres -involving ATR, and p53- ultimately 
leading to cellular senescence (Martinez et al., 2009, Sfeir et al., 2009).  
TRF2, structurally similar to TRF1, specifically prevents the activation of ATM at 
telomere ends (Denchi and de Lange, 2007, Dimitrova and de Lange, 2009, Okamoto et 
al., 2013), is involved in telomere heterochromatin maintenance (Benetti et al., 2008) and 
helps the formation of the above-mentioned t-loop structures, whose recent evidence 
strongly suggests to be required for TRF2 functions (Doksani et al., 2013). Trf2 deletion in 
mouse cells leads to NHEJ-mediated telomeric fusion events independent of replication 
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fork stalling (Celli et al., 2006). In addition, constitutive Trf2 deficiency in mice leads to 
embryonic lethality in a p53-independent manner (Celli and de Lange, 2005). 
RAP1 is localized to telomeres through its protein interaction with TRF2 (Chen et al., 
2011). RAP1 is the only shelterin protein whose depletion does not lead to embryonic 
lethality in mice (Martinez et al., 2010), nonetheless resulting in adult mice undergoing 
increased telomere shortening and DDR activation, therefore suggesting a role in telomere 
homeostasis.  
POT1 directly binds to the 3’ single-stranded G-overhang of telomeres (Baumann and 
Cech, 2001, Lei et al., 2004) favoured by the formation a stable heterodimer with TPP1 in 
vivo (Hockemeyer et al., 2007, Chen et al., 2017). POT1 prevents ATR-mediated DDR 
activation at telomeres and regulates the length of the 3′ G-strand overhang (Palm et al., 
2009); its loss leads to senescence induction in a p53-dependent manner (Wu et al., 2006) 
with telomere shortening and increased chromosomal fusions (Hockemeyer et al., 2008). 
TPP1 functions as a protein hub that coordinates the end-protection functions of the 
shelterin complex. Apart from the above-mentioned function of favouring the binding of 
POT1 to telomeric ssDNA, TPP1 plays a fundamental role in regulating telomerase 
activity through its oligonucleotide/oligosaccharide binding (OB) fold domain (Zhong et 
al., 2012).  
Similar to TPP1, TIN2 is an important protein for the maintenance of the shelterin complex 
stability. TIN2 binds both to TRF1 and TRF2, stabilizing them at telomeres (Ye et al., 
2004). In addition, TIN2 also binds TPP1 and is required for the recruitment of 
TPP1/POT1 to the shelterin complex (Takai et al., 2011). As a consequence, when TIN2 is 
depleted, ATR is activated and excessive 3′ overhang is generated (caused by TPP1/POT1 
loss) while in parallel TRF2 destabilization also induces ATM activation (Frescas and de 
Lange, 2014). 
Interestingly, a very recent report has described a new specific telomere-associated protein 
named telomeric zinc finger-associated protein (TZAP), which directly binds double-
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stranded telomeric DNA via zinc finger domains (Li et al., 2017). It preferentially binds 
long telomeres – thus competing with TRF1 and TRF2 for the binding to dsTTAGGG 
repeats – as they show a lower density of shelterin components compared to short 
telomeres. When localized at the telomeres, TZAP triggers a telomere trimming 
mechanism, generating a rapid deletion of TTAGGG repeats thus regulating telomere 
length by setting an upper length limit when the shelterin complex is not sufficient to 
prevent TZAP from binding to telomeres (Li et al., 2017). 
1.3.2 Telomere length maintenance mechanisms 
Every cell division causes a decrease of telomere length as a result of the DNA replication 
machinery inability to copy the lagging-strand of the most distal telomeric sequences of 
each chromosome (Harley et al., 1990), a circumstance known as the end replication 
problem (Watson, 1972). This biological phenomenon, common to most somatic cells in 
the human body, in the absence of a telomere-elongating mechanism, causes telomeres to 
shrink to a critical length that may ultimately lead to a telomere dysfunction-induced 
senescence (d'Adda di Fagagna et al., 2003) also known as replicative senescence (further 
explained in section 1.4.1.). 
Telomere elongation by telomerase is likely the most studied telomere maintenance 
mechanism (TMM). Human telomerase is an RNA-containing reverse transcriptase that 
consists of an RNA component (hTR, 451 nt long), a reverse transcriptase catalytic subunit 
(hTERT) and the accessory proteins dyskerin, NOP10, NHP2, and GAR. In normal 
conditions, human telomerase activity is restricted to embryogenesis and its expression is 
switched off in most cells, with the exception of activated lymphocytes, adult stem cells 
and germ line (Wright et al., 1996). Nonetheless, in human cancer, 80-85% of tumours rely 
on telomerase for their TMM.  
Most enzymes find their substrates by simple diffusion throughout the cell, however, a 
normal human cell in late S phase accounts for approximately 250 telomerases and 184 
telomeres (Xi and Cech, 2014); which suggests telomerase being actively recruited to 
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telomeres rather than stochastically encountering them. As mentioned above (section 
1.3.1), TPP1 is the key shelterin component necessary for telomerase recruitment to 
telomeres (Xin et al., 2007, Zhong et al., 2012). Telomerase is known to exhibit a 
preference for short telomeres, indicating a switch between non-extendible to extendible 
telomere states. The hexameric repeat addition processivity of telomerase is thought to add 
50–60 nt to most telomeres after a single initiation event, and it is accelerated at extremely 
short telomeres, which allows cells to rapidly elongate them (Teixeira et al., 2004). The 
CTC1-STN1-TEN1 (CST) complex, through the binding of telomeric ssDNA, has been 
proposed as one mechanism by which an upper limit of telomere synthesis is set, allowing 
the displacement of telomerase once the overhang has reached a critical length (Chen et al., 
2012). A second negative regulator of telomere length in human cells is TERRA RNA 
(discussed in section 1.3.4), which by directly binding telomerase, has been proposed to 
inhibit telomerase activity in cis (Schoeftner and Blasco, 2008, Redon et al., 2010). Lastly, 
telomere structures like t-loops and G quadruplexes have also been recently reported to 
prevent telomerase from accessing the telomeres (Jun et al., 2013, Doksani et al., 2013). 
10-15% of human cancers achieve replicative immortality by relying on a telomerase-
independent TMM. This mechanism, named alternative lengthening of telomeres (ALT), is 
an HR-driven pathway where telomeric overhangs invade another telomeric DNA, and use 
it as a template for DNA synthesis (Cho et al., 2014). Relatively little is known about the 
mechanism of ALT-mediated telomere synthesis. ALT activity is associated with a set of 
molecular markers: ALT-Associated PML Bodies (APBs), which are nuclear hubs 
detectable by fluorescence microscopy hypothesized to enable ALT-mediated HR and 
telomere extension; extrachromosomal telomeric repeats (ECTRs), among them, C- circles 
(circular partially single-stranded [CCCTAA]n DNA sequences) are the most commonly 
assayed ECTR and are detectable by rolling circle amplification assays using a Φ29 DNA 
polymerase (Henson et al., 2009); Telomere-Sister Chromatid Exchange (T-SCE), which 
are telomeric crossover events (Londono-Vallejo et al., 2004) detectable by chromosome 
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orientation fluorescence in situ hybridization (CO-FISH); and Telomere Dysfunction-
Induced Foci, which are telomeric DDR foci, in ALT likely caused by telomere replication 
stress (Dilley et al., 2016). Chromatin compaction is decreased at ALT telomeres, and this 
has been associated with an upregulation of telomere transcription (Episkopou et al., 
2014). Furthermore, ALT cancers are highly correlated with mutations in the 
ATRX/DAXX complex (a chromatin-remodeling complex known to aid deposition of 
H3K9me3 at telomeres) and histone variant H3.3 (Lovejoy et al., 2012, Heaphy et al., 
2011), whose telomeres tend to be heterogeneous in length; some of them are very short, 
but others can reach up to 100 Kb. Importantly, reintroduction of ATRX into ATRX-
mutated ALT cancer cell lines represses the formation of ALT molecular markers (Napier 
et al., 2015, Clynes et al., 2015), indicating an important role of ATRX in repressing ALT. 
1.3.3 The role of telomeres in immortality and cancer 
Very recent data are opposing the idea that replicative immortality, relying on either 
telomerase expression or ALT activity TMMs, is a hallmark of cancer cells. Several 
independent laboratories have reported that a set of metastatic and cancer-derived cell lines 
do not exert a TMM, supporting the idea that long telomeres per se are sufficient for 
tumour formation and maintenance (Viceconte et al., 2017, Dagg et al., 2017). In support 
of this idea, bioinformatics analysis of a large cohort of human tumours (18,430 samples) 
has recently reported that approximately a fifth of the samples analysed neither expressed 
telomerase (as shown by the absence of hTERT mutations) nor harboured alterations in 
ATRX or DAXX genes (Barthel et al., 2017). These new findings add an additional layer 
of complexity for cancer treatment as in some cases prevention of telomere shortening is 
not required for oncogenesis neither for cancer progression. 
1.3.4 Transcription at telomeres  
Telomeres from yeast to humans are transcribed into telomeric repeat-containing RNA 
(TERRA), which is an RNA transcript originated from several subtelomeric regions 
located close to chromosome ends and is composed of tandem UUAGGG repeat sequences 
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ranging in size from 100 bases to over 9 Kb in mammals (Azzalin et al., 2007, Porro et al., 
2014). Approximately 7% of human TERRA transcripts are polyadenylated (Azzalin and 
Lingner, 2008) whereas the majority of yeast TERRA molecules carry a 3’ poly(A) tail 
(Luke et al., 2008), and most human and yeast TERRA transcripts carry a 7-
methylguanosine (m7G) cap structure in their 5’ end (Feuerhahn et al., 2010); all these 
features stabilise TERRA molecules. By interacting with RNA Pol II, TRF1 positively 
regulates TERRA expression levels, while heterochromatin represses TERRA transcription 
(Schoeftner and Blasco, 2008).  
Importantly, in human cells, telomere dysfunction induced by removal of TRF2 leads to 
increased TERRA levels at all transcribed telomeres (Feretzaki and Lingner, 2017, Porro et 
al., 2014). Furthermore, the TRF2 homodimerization domain, which induces chromatin 
compaction and prevents DDR activation (Denchi and de Lange, 2007), represses TERRA 
transcription independently of p53 and does not rely on ATM-dependent DDR signalling 
(Porro et al., 2014). The UUAGGG-repeat array of TERRA transcripts binds directly to 
SUV39H1 H3K9 histone methyltransferase, sustaining the accumulation of H3K9me3 at 
dysfunctional telomeres (Porro et al., 2014). Moreover, TERRA has been reported to 
accumulate H3K9me3 at functional telomeres (Arnoult et al., 2012), indicating a role of 
TERRA in heterochromatin reorganization at telomeres. 
Recently, gapmer-Locked Nucleic Acid (LNAs) with a telomere sequence have been used 
to fully deplete TERRA in mouse cells (Chu et al., 2017); this leads to an increase of 
telomere dysfunction as well as a greater occurrence of other multiple telomeric 
pathologies such as loss of the telomeric repeat sequences, duplications of telomeric 
repeats at chromosomal ends and fusions between sister chromatid telomeres. These 
findings altogether indicate a functional role of TERRA transcripts for the maintenance of 
telomere integrity.  
In addition, full depletion of TERRA has been reported to downregulate subtelomeric 
genes and internal chromosome target genes, indicating a role for TERRA to modulate 
 36 
transcription (Chu et al., 2017). TERRA has been shown to associate with proteins 
belonging to epigenetic complexes, telomeric factors, DNA replication complexes and cell 
cycle regulators. In mouse stem cells, ATRX stands out as a major TERRA-interacting 
protein partner. TERRA regulates ATRX association with telomeric chromatin as 
depletion of TERRA causes increased ATRX localization to telomeres (Chu et al., 2017), 
suggesting functionally antagonistic roles of TERRA and ATRX at telomeres. Thus, in 
addition to maintaining telomere integrity in normal cells, TERRA expression, by 
specifically suppressing ATRX, may promote ALT in cancer cells, a hypothesis supported 
by the fact that cells harbouring ALT activity accumulate higher TERRA levels (Arora et 
al., 2014). 
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1.4 Cellular senescence and Hutchinson-Gilford progeria syndrome 
1.4.1 Cellular senescence and aging 
Strong evidence indicates the presence of senescent cells in vivo and their contribution to 
organismal aging and pathological conditions like cancer or chronic diseases (Kirkland, 
2016, Goldman et al., 2013), and also in normal and tumour tissues following DNA-
damaging chemotherapy (Collado and Serrano, 2010). Cellular senescence was originally 
described by Leonard Hayflick and collaborators as the limited proliferative potential 
shown by normal cultured cells (Hayflick, 1965). Mortal cells in fact undergo cellular 
senescence (often accompanied by an enlarged and flattened morphology) in response to a 
wide range of different types of stresses, such as dysfunctional telomeres, DNA damage 
and oncogene expression. The hallmark of cellular senescence is the inability of cells to 
progress through the cell cycle, which leads to a permanent growth arrest that can be 
monitored by 5-bromodeoxyuridine (BrdU) or H-thymidine incorporation (which indicates 
the extent of de novo DNA synthesis) or by the expression levels of proliferation markers 
like PCNA or Ki-67. The expression of senescence-associated-β-galactosidase (SA-β-gal), 
a lysosomal β-galactosidase whose activity (increased in senescent cells and detectable at 
pH 6) can be measured by histochemical staining, is the first marker ever used to 
specifically detect senescent cells (Dimri et al., 1995). In addition, the cell cycle inhibitor 
p16 - a known regulator of senescence encoded by the CDKN2/INK4a locus - is currently 
used to identify senescent cells (Krishnamurthy et al., 2004). p21, another cell cycle 
regulator (encoded by CDKN1A gene), is also often expressed in senescence (Campisi, 
2001). 
Importantly, senescence is associated with the acquisition of a senescence-associated 
secretory phenotype (SASP), which entails the secretion of cytokines, bradykines, 
miRNAs, prostenoids, chemokines that attract immune cells and extracellular matrix-
damaging molecules, including proteases (Campisi and d'Adda di Fagagna, 2007, Xu et al., 
2015a, Xu et al., 2015b, Coppe et al., 2006, Tchkonia et al., 2013). Furthermore, senescent 
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cells display a cytologically detectable chromatin reorganization phenomenon known as 
senescence-associated heterochromatin foci (SAHF) (Narita et al., 2003), which in some 
senescent cells relies on a maintained p21 and p16-dependent activation of the 
retinoblastoma (pRB) protein.  
Senescent cells also exert large and persistent DDR foci, so-called senescence-associated 
DNA-damage foci (SDF), which are known to play an essential role both in senescence 
initiation and maintenance (d'Adda di Fagagna et al., 2003, Herbig et al., 2004, Galbiati et 
al., 2017, Sedelnikova et al., 2004, Fumagalli et al., 2012, von Zglinicki et al., 2005).  
In proliferating human cells, progressive telomere attrition ultimately leads to exposed free 
double-stranded chromosome ends (d'Adda di Fagagna et al., 2003), triggering a persistent 
and irreparable telomeric DDR (Fumagalli et al., 2012); the so-called replicative 
senescence. In fact, replicative senescence is not caused by the telomere length average of 
a cell but by the presence of a small number of telomeres sufficiently short to trigger a 
DDR that activates a senescent signal (Hemann et al., 2001, Herbig et al., 2004).  
In cellular senescence induced by IR, in which multiple random DSBs are generated 
activating the ATM-p53-p21 pathway, most DSBs are repaired hours after irradiation. 
However, a subset of damaged sites, mostly telomeres, result in persistent DDR signalling 
as they are hard to repair (Fumagalli et al., 2012), and this impedes cell cycle progression 
ultimately leaving cells in a permanent growth arrest.  
In recent years, new strategies for targeting senescent cells (named senotherapies) have 
been developed to directly kill them, either by apoptotic (senoptosis) or by non-apoptotic 
(senolysis) means (Zhu et al., 2015). Senotherapies, for instance, have been used to 
eliminate senescent cells that may be preneoplastic, reducing cancer risk from senescence 
escape (Liu and Sharpless, 2012). On the other hand, senescence is beneficial in some 
contexts, such as wound repair (Demaria et al., 2014) and in embryogenesis (Munoz-Espin 
et al., 2013, Storer et al., 2013), therefore these cells should be exempted from been 
 39 
targeted by senotherapies, one way, for instance, by delivering drugs directly to the sites of 
pathology.  
1.4.2 Hutchinson-Gilford progeria syndrome 
Hutchinson–Gilford Progeria Syndrome (HGPS) is a rare premature aging disorder, which 
affects 1 in 4-8 million new-borns. Within the first year of life, children start to exhibit 
distinctive clinical pathological features such as, partial alopecia progressing towards total 
alopecia, loss of subcutaneous fat, progressive joint contractures and nail dystrophy, while 
displaying a normal motor and mental development (Hennekam, 2006). Eventually, HGPS 
patients die at an average age of 14 years due to myocardial infarction, heart failure or 
progressive atherosclerosis (Hennekam, 2006). HGPS is a human genetic disease caused 
by heterozygous mutations of the LMNA gene encoding lamin A and lamin C resulting in 
aberrant splicing which leads to the expression of a truncated form of Lamin A protein 
called progerin (Figure 5). 
 
Figure 5. Consequences of progerin expression. 
Progerin accumulation leads to nuclear envelope morphological abnormalities, misregulated gene expression, 
altered DNA repair, DNA damage accumulation, genomic instability and telomere shortening and 
dysfunction. These progerin-driven defects ultimately end up limiting the cellular proliferative capacity of 
the cell. 
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A de novo single-base mutation within exon 11 of LMNA (c.1824C > T) was the first 
HGPS driver mutation ever reported (De Sandre-Giovannoli et al., 2003, Eriksson et al., 
2003) activating a cryptic splice site and resulting in a deletion of 50 amino acids near the 
C-terminus of Prelamin A (a 664-residue precursor of Lamin A). To date c.1824C > T 
remains the most common mutation, with also other driver mutations in LMNA gene 
reported in HGPS patients (Moulson et al., 2007, Reunert et al., 2012, Bar et al., 2017, 
DeBoy et al., 2017).  
Compared to normal fibroblasts, HGPS fibroblasts exhibit nuclear shape abnormalities and 
severe loss of heterochromatin (Goldman et al., 2004) caused by reduced levels of 
Heterochromatin Protein 1 alpha (HP1α), decreased marks of histone H3 trimethylated at 
lysine 27 (H3K27me3) due to downregulation of histone methyltransferase Enhancer of 
Zeste Homolog 2 (EZH2) and low levels of histone H3 trimethylated at lysine 9 
(H3K9me3). Notably, progerin expression also causes aberrant activation of the nuclear 
factor kappa-light-chain-enhancer of activated B cells (NF-kB) and Notch signaling 
pathways (Prokocimer et al., 2013), premature senescence (Cao et al., 2007, Gonzalo and 
Kreienkamp, 2015) and mitochondrial dysfunction (Rivera-Torres et al., 2013). Progerin 
accumulation is known to affect stem cell dysfunction both in vitro (Zhang et al., 2011, 
Pacheco et al., 2014, Scaffidi and Misteli, 2008) and in the skin of mouse models of 
progeroid laminopathies (Rosengardten et al., 2011, Espada et al., 2008, Lavasani et al., 
2012). 
Importantly, HGPS nuclei accumulate DNA damage and exhibit chromosomal instability 
caused by deficiencies in the DDR and in the mechanisms of DSB repair (Liu et al., 2005) 
and by accelerated telomere shortening (Decker et al., 2009) and dysfunction (Benson et 
al., 2010). Telomerase expression or p53 inactivation upon progerin expression reduces 
DNA damage and increases cell proliferation rates (Kudlow et al., 2008), suggesting that 
telomere dysfunction and checkpoint activation play important roles in HGPS. Indeed, 
telomerase expression restores senescence-associated misregulated genes (Kudlow et al., 
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2008), the proliferative defect associated with progerin expression (Chojnowski et al., 
2015) and prevents progerin-driven heterochromatin loss (Kudlow et al., 2008). In 
addition, progerin reduces the cellular expression of Lamina-associated polypeptide-a 
(LAP2α) and its association with telomeres (Chojnowski et al., 2015) and ectopic 
expression of LAP2α rescues progerin-driven proliferation defects and H3K27me3 loss 
(Chojnowski et al., 2015).  
Thus, telomere dysfunction and its consequences is emerging as a key feature in HGPS. 
New strategies to control telomere dysfunction, other than telomerase expression (hard to 
achieve and with potential extra-telomeric effects such as its impact on WNT/β-catenin 
pathway; (Saretzki, 2014)), are fundamental to understand the true contribution of telomere 
dysfunction in the pathogenesis of the disease and design efficacious potential therapeutic 
approaches. 
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2 Materials	and	methods	
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2.1 Cell culture 
Mouse embryonic fibroblast (MEF) cell lines (Trf2F/+ and Trf2F/F MEFs), which carry a 
Cre recombinase (Rosa26-CreERT2), a gift from Eros Lazzerini Denchi, SCRIPPS, La 
Jolla, California, USA (Okamoto et al., 2013), were grown in DMEM without phenol red 
(as it has weak estrogenic activity and bears a structural resemblance to 4-
hydroxytamoxifen) supplemented with 10% fetal bovine serum (FBS) and 1% glutamine. 
They are MEF-derived cell lines in which either one or both Trf2 alleles are loxP-flanked, 
and that constitutively express a CRE recombinase fused to the ligand binding domain of 
the estrogen receptor (ER). For the induction of Trf2 knock out, cells were grown in the 
presence of 4-hydroxytamoxifen (600 nM) for 48 hours, to allow CRE-ER to translocate 
into the nucleus and to generate the Trf2+/- and Trf2-/- cell lines. 
T19 cells, a gift from Titia de Lange, Rockfeller University, New York, NY, USA (van 
Steensel et al., 1998), were grown in DMEM supplemented with 10% TET-system 
approved FBS, 1% L-glutamine, G418 (150 µg/ml) or hygromycin (90 µg/ml), 
alternatively. They are a HT1080-derived clonal fibrosarcoma cell line with a Tet-OFF 
system, which express the tetracyclin-controlled transactivator (tTA) and the dominant 
negative allele of TRF2 (TRF2 ΔBΔM, a mutant allele lacking the basic and myb domains 
of TRF2) under the tetracycline-controlled promoter. T19 cells were grown in the presence 
of doxycycline (100 ng/ml), which impedes the binding of the tTA to the promoter. In 
order to express TRF2 ΔBΔM, T19 cells were grown in the absence doxycyclin, and 
telomere uncapping was achieved 7-8 days after doxycyclin removal.  
BJ cells (The American Type Culture Collection, ATCC) were grown in MEM 
supplemented with 10% FBS, 1% L-glutamine, 1% non-essential amino acids (NEAA), 
sodium pyruvate (C3H3NaO3) 1mM. Phoenix amphotropic (ATCC) cells were grown in 
DMEM, supplemented with 10% FBS and 1% L-glutamine. 
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HGPS patient-derived human primary fibroblasts, a gift from Giovanna Lattanzi, Istituto di 
Genetica Molecolare, Consiglio Nazionale delle Ricerche, Bologna, Italy, were grown in 
DMEM supplemented with 20% FBS and 1% L-glutamine.  
All cells were grown at 37°C, 5% CO2.  
2.2 RNA isolation 
Total RNA from cultured cells was extracted with RNeasy Mini Kit (Qiagen) or with 
Maxwell® RSC miRNA Tissue Kit (Promega) for messenger RNA detection. mirVana 
miRNA Isolation kit (Life Technologies) or Maxwell® RSC miRNA Tissue Kit (Promega) 
was used for DDRNA and dilncRNA detection, according to the manufacturer’s 
instructions. RNA extracted with mirVana miRNA Isolation kit using the Enrichment 
Procedure for Small RNAs was used as starting material for Target-Enrichment of small 
RNAs (TEsR). RNA was quantified with a NanoDrop spectrophotometer (Thermo 
Scientific). An Agilent 2100 Bioanalyzer instrument, which is a micro-capillary based 
electrophoretic cell, was used to assess the quality of RNA. 
2.3 Real-time quantitative PCR for gene expression 
1 µg of total cell RNA was reverse transcribed using SuperScript VILO cDNA Synthesis 
Kit. A volume corresponding to 10 ng of initial RNA was used for each qPCR reaction 
using GoTaq qPCR Master Mix (Promega) or LightCycler® 480 SYBR Green I Master 
(Roche) on a Roche LightCycler 480 detection instrument. Each reaction was performed in 
three technical replicates. Human ribosomal protein large P0 (Rplp0) and mouse beta-2 
microglobulin (B2M) were used as control transcripts for normalization. Primers 
sequences (5’-3’ orientation) were: 
Mouse Dicer Fw: GCAAGGAATGGACTCTGAGC 
Mouse Dicer Rv: GGGGACTTCGATATCCTCTTC  
Mouse Drosha Fw: CGTCTCTAGAAAGGTCCTACAAGAA 
Mouse Drosha Rv: GGCTCAGGAGCAACTGGTAA  
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Mouse B2M Fw: CTGCAGAGTTAAGCATGCCAGTA 
Mouse B2M Rv: TCACATGTCTCGATCCCAGTAGA 
Human Dicer Fw: GCAAAGCAGGGCTTTTCAT 
Human Dicer Rv: AGCAACACAGAGATCTCAAACATT 
Human Drosha Fw: TGCACACGTCTAACTCTTCCAC 
Human Drosha Rv: GGCCCGAGAGCCTTTTATAG 
Human Rplp0 Fw: TTCATTGTGGGAGCAGAC 
Human Rplp0 Rv: CAGCAGTTTCTCCAGAGC 
Human Progerin Fw: ACTGCAGCAGCTCGGGG 
Human Progerin Rv: TCTGGGGGCTCTGGGC 
Human p21 Fw: TCACTGTCTTGTACCCTTGTGC 
Human p21 Rv: GGCGTTTGGAGTGGTAGAAAT 
Human p16 Fw: CTTTCAATCGGGGATGTCTG 
Human p16 Rv: GTGGACCTGGCTGAGGAG 
Human IL-1A Fw: GGTTGAGTTTAAGCCAATCCA 
Human IL-1A Rv: TGCTGACCTAGGCTTGATGA 
Human IL-6 Fw: CCAGGAGCCCAGCTATGAAC 
Human IL-6 Rv: CCCAGGGAGAAGGCAACTG 
Human IL-8 Fw: TTGGCAGCCTTCCTGATTTC 
Human IL-8 Rv: TCTTTAGCACTCCTTGGCAAAAC 
2.4 Real-time quantitative PCR for small RNAs 
5 µg of total cellular RNA were run and fractionated on a 10% polyacrylamide, 7 M Urea 
gel to allow small RNA separation under denaturing conditions and RNA species shorter 
than 40 nucleotides were gel-extracted by incubating the gel fraction overnight in an 
Elution Buffer (0.3 M NaCH3CO2 pH 5.5, 0.1 mM EDTA, 0.2% sodium dodecyl sulphate 
(SDS)) followed by ethanol precipitation. 10 pg of an RNA spike-in was added to all 
samples before cellular RNA was loaded on the gel in order to normalize for the efficiency 
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of RNA extraction from gel. cDNA was synthesized using the miScript II RT kit (Qiagen) 
with HiSpec buffer. PCR was performed using the miScript PCR system (Qiagen) 
accordingly to the manufacturer’s instructions. Each reaction was performed in three 
technical replicates. mir29b or mir17 was used as a control gene for normalization. Primers 
sequences (5’-3’ orientation) were as follows: 
mir29b Fw: TAGCACCATTTGAAATCAGTGTT 
mir17 Fw: CAAAGTGCTTACAGTGCAGGTAG 
spike-in Fw: CGAATTCCACAAATTGTTATCC 
teloG Fw: TAGGGTTAGGGTTAGGGT 
teloC Fw: CCCTAACCCTAACCCTAA 
2.5 Strand-specific real-time quantitative PCR 
Total cellular RNA extracted from mirVana miRNA Isolation kit (Life Technologies) or 
Maxwell® RSC miRNA Tissue Kit (Promega) was used for dilncRNA detection. Samples 
were treated with DNase I (Thermo Scientific) at 37°C for 1 hour to remove any potential 
residual genomic DNA contamination (1 unit of DNase I per 1 µg of RNA). 1 µg of total 
RNA was reverse-transcribed using the Superscript First Strand cDNA synthesis kit 
(Invitrogen) with strand-specific primers. To amplify telomeric repeats I adapted a 
technique described in (Cawthon, 2002), which allows the generation of a fixed-length 
telomeric amplification product. For reverse-transcription the following primers were used: 
Rplp0 Rv for the detection PCR of Rplp0 mRNA; teloC Rv for the detection of the G-rich 
telomeric dilncRNA; teloG Rv for the detection of C-rich telomeric dilncRNA. Reverse 
transcription reactions must be performed in separate tubes to detect each telomere strand, 
as the addition of both teloC Rv and teloG Rv in a single reaction does not allow to 
distinguish between strands at the qPCR level. Quantitative PCR was performed using 
LightCycler® 480 SYBR Green I Master (Roche). For each reaction, 50 ng of cDNA were 
used. Each reaction was performed in triplicate. Rplp0 was used as a control gene for 
normalization. Primer sequences (5’-3’ orientation) were as follows:  
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Rplp0 Fw: TTCATTGTGGGAGCAGAC 
Rplp0 Rv: CAGCAGTTTCTCCAGAGC 
teloC Rv: CCCTAACCCTAACCCTAA 
teloG Rv: TAGGGTTAGGGTTAGGG 
telo Fw: CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT 
telo Rv: GGCTTGCCTTACCCTTACCCTTACCC TTACCCTTACCCT 
2.6 Target-Enrichment of small RNAs (TEsR) 
Two linkers were ligated to the two ends of the RNA molecules in the MEFs RNA samples 
extracted with mirVana miRNA Isolation kit using the Enrichment Procedure for Small 
RNAs. The 3’ end of the starting RNA was ligated to a monoadenylated DNA linker by a 
T4 RNA ligase 2 truncated enzyme (NEB) by incubating for 1 hour at 25°C. The 5’ RNA 
linker was then ligated by the use of a T4 RNA ligase 1 (NEB) to the target RNA at 20°C 
for 1 hour, after the removal of the 5’ cap structure by a Tobacco Acid Pyrophosphatase 
(Epicentre), incubated at 37°C for 1 hour. The 3’ linkers allowed for cDNA synthesis using 
PrimeScript RT-PCR Kit (Takara) and reverse transcription reaction was incubated at 44°C 
for 1 hour. Subsequent PCR amplification using Phusion® High-Fidelity DNA Polymerase 
(NEB) was peformed using the following cycling conditions: 98°C 2 minutes; 22 cycles 
of: 98°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds; 72°C for 5 minutes; 
hold at 4°C. To capture the amplified cDNA targets, I produced and used complementary 
RNA baits containing biotin-labeled nucleotides. The RNA baits were produced by using 
AMbion MAXIscript T7 In Vitro Transcription kit (Life Technologies) and Biotin RNA 
labelling Mix (Roche). A T7-promoter-containing dsDNA was used as template for in vitro 
transcription by incubating at 37°C for 1 hour. RNA baits and cDNA targets were 
incubated at 37°C for 48 hours in the presence of SUPERase-inhibitor (Life Technologies) 
and of the following blocking agents: Human Cot-1 (Life Technologies), UltraPure™ 
Salmon Sperm DNA Solution (Thermo Scientific) and a 200 µM Customized Block. The 
hybrid RNA-cDNA molecules were captured by Dynabeads® MyOne™ Streptavidin C1 
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(Life Technologies) beads, while non-targeted cDNAs were washed away. Captured 
cDNAs were then indexed by PCR with Script Index PCR primers (Illumina) and 
sequenced by a MiSeq (Illumina) sequencer. Oligonucleotide sequences (5’-3’ orientation) 
were: 
3’ DNA linker: AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC-Amine 
5’ RNA linker: ACACUCUUUCCCUACACGACGCUCUUCCGAUCU 
RT primer: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
PCR Fw: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCT 
CTTCCGATCT 
PCR Rv: CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAAC 
CGCTCTTCCGATCT 
Customized Block Fw: AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTAC 
ACGACGCTCTTCCGATCT 
Customized Block Rv: CAAGCAGAAGACGGCATACGAGATCGTGATGTGACTGGA 
GTTCAGACGTGTGCTCTTCCGATCT 
RNA bait*: CAUGAGCAUGAGUAGNNNNNNNNNNNNNNNNNNNNNNNNNNGUA 
GCUUGGCAUACC 
ScriptSeq reverse index adapter primer*: CAAGCAGAAGACGGCATACGAGATXXX 
XXXGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT 
* Customisable RNA bait sequences and sample index sequences are shown in bold font. N represents a 
given nucleotide according to the sequence of the transcriptome aiming to enrich. X represents a given 
nucleotide according to the complete list of index sequences provided by ScriptSeq™ Index PCR Primers. 
2.7 Short interfering RNA transfection 
The RNA interference (RNAi) is composed of several categories of RNA, such as miRNA, 
siRNA and piRNA (He and Hannon, 2004). In cultured cells, short synthetic siRNAs are 
typically used for downregulation of endogenous mRNA. For siRNA transfection, I plated 
cells so that at the day of transfection they are at an approximate confluency of 30-40%. At 
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day of transfection, growth medium was removed from the cells and substituted with 0.75 
volumes of fresh culture medium. For each transfection reaction, I mixed 0.125 volumes of 
Opti-MEM with siRNA oligos (5 or 20 nM final concentration) and 0.125 volumes of 
Opti-MEM with Lipofectamine RNAiMAX transfection reagent (Life technologies). The 
mix was incubated for 20 minutes at room temperature (RT) to allow the formation of 
siRNA-containing lipid particules and subsequently added to the cells were the fresh 
medium was previously added. I used ON-TARTGETplus SMARTpool siRNA 
oligonucleotides (Dharmacon), which for each mRNA, a set of four siRNAs are used. 
Sequences were as follows (5’-3’ orientation):  
siDicer human UAAAGUAGCUGGAAUGAUG;  
GGAAGAGGCUGACUAUGAA; GAAUAUCGAUCCUAUGUUC; 
GAUCCUAUGUUCAAUCUAA 
siDrosha human CAACAUAGACUACACGAUU; 
CCAACUCCCUCGAGGAUUA; GGCCAACUGUUAUAGAAUA;  
GAGUAGGCUUCGUGACUUA 
siDicer1 mouse GGUAGACUGUGGACCGUUU; 
GGAAAUACCUGUACAACCA; GCAAUUUGGUGGUUCGUUU; 
ACAGGAAUCAGGAUAAUUA  
siDrosha mouse UGGAAGGAGUUACGCUUUA; 
GGAAUCCGCCACAGCAUUU; GUGAUCACUUUCCCGAUUA; 
UAAUGCACCUGGACAAGUU 
siControl (siGFP) GCAAGCUGACCCUGAAGUUCAU 
2.8 Transfection of Antisense oligonucleotides (ASOs) 
Locked Nucleic Acid (LNA) are nucleic acids analogues which contain a bridge between 
the 2' oxygen and 4' carbon that “lock” the ribose in a Watson-Crick-binding optimal 
conformation. This structure confers LNA high thermal stability and increases their 
melting temperature allowing a higher binding affinity for a complementary target 
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sequence. For these reasons, LNAs are used as Antisense Oligonucleotides (ASOs), which 
by binding the target nucleic acid sequence, inhibit their further processing and/or 
function. LNA ASOs were transfected as reported for siRNAs (see the “Short interfering 
RNA transfection” section). As for siRNA transfections, for each transfection reaction, I 
used 20 nM of LNA ASOs. In order to prevent the formation of secondary structures of the 
oligos, Opti-MEM with ASOs was incubated at 95°C for 5 minutes and immediately 
placed on ice for 5 minutes. The sequences for the LNA ASOs were as follows (5’-3’ 
orientation): 
Control: TTATCCGCTCACAATTCCACAT 
Telo C: CCCTAACCCTAACCCTAACCC 
Telo G: GGGTTAGGGTTAGGGTTAGGG 
2.9 Retroviral transduction 
Phoenix amphotropic cells were used as a retrovirus producer cell line, which is based on 
the HEK 293T cell line that produces the gag, pol and envelope proteins which allow the 
formation of the retrovirus. The retroviral expression vectors used (pLPC-LaminA and 
pLPC-Progerin, Addgene plasmids numbers 69059 and 69061 respectively) included the 
viral packaging signal, the Lamin A or Progerin genes under the LTR promoter and a 
puromycin resistance marker. Phoenix amphotropic cells were plated so that at time of 
transfection they were approximately 60% confluent. I used the calcium phosphate 
(Ca3(PO4)2) method to transfect Phoenix amphotropic cells, which is based on the 
formation of a precipitate containing Ca3(PO4)2 and DNA that adheres to the cell surface 
facilitating its internalization through endocytosis. The precipitate is obtained by slowly 
dropping a solution containing calcium chloride (CaCl2) and plasmidic DNA (10 µg for 
each 10-cm plate of Phoenix amphotropic cells) in a HEPES-buffered saline (HBS) 
solution containing sodium phosphate (Na2PO4). In order to increase the virus yield by 
affecting the intracellular exocytic pathways caused by an increase of endosomal pH, 
chloroquine was added to the medium at a final concentration of 40 µM. The 
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HBS/DNA/CaCl2 solution was added to the Phoenix amphotropic cells within 5 minutes of 
preparation. The day after transfection, growth medium was replaced with 5 ml of fresh 
medium per 10-cm dish of Phoenix amphotropic cells to concentrate viral particles in the 
supernatant. 48 hours post-transfection, the concentrated viral supernatants were collected 
and filtered with a 0.45 µm filter to remove all potential Phoenix amphotropic cells present 
in the supernatant. Polybrene at a final concentration of 8 µg/ml was added to the filtered 
supernatant to increase the infection efficiency by allowing the viral glycoproteins to bind 
more efficiently to their receptors. These supernatants were used to perform four rounds of 
infections in BJ human fibroblasts for a period of 2 days. After infection, BJ cells were 
grown for two days in the presence of puromycin at a concentration of 2 µg/ml to select for 
the successfully infected cells. 
2.10 Protein immunoblotting 
Cells were lysed in Laemmli buffer, an aqueous solution containing 2% SDS, 10% 
glycerol and 60 mM Tris HCl pH 6.8. SDS allows the denaturation of proteins leaving a 
uniform negative charge throughout the length of the polypeptide, which helps the 
separation of proteins by electrophoresis based on their molecular weight. To measure the 
concentration of proteins in the samples, I used the biochemical Lowry protein assay in 
which the total protein concentration is exhibited by a color change of the sample solution 
in proportion to protein concentration. 30 µg of whole cell extracts were run in running 
buffer (25 mM Tris HCl, 0.2 M glycine, 0.1% SDS, pH 8.3) on a 7.5%, 12% or 4-20% 
Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad), which allowed the resolution 
of proteins of 40-200 kDa, 20-120 kDa or 10-200 kDa respectively. After running, the 
proteins were transferred to a nitrocellulose membrane in a wet electroblotting instrument 
using an aqueous transfer buffer containing 25 mM Tris HCl, 0.2 M Glycine and 20% 
methanol. Transferred membranes were temporarily stained with Ponceau to evaluate the 
efficiency of transfer. Membrane blocking of unspecific sites and primary and secondary 
antibody incubations were carried out in 5% milk in TBST (0.1% Tween in Tris-Buffered 
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Saline). All the washes between incubations were performed in TBST. The primary 
antibody was used to specifically detect the protein of interest, whereas the secondary 
antibody, linked to a horseradish peroxidase, was used to detect a species-specific antigen 
of the primary antibody. The localized light produced by the peroxidase in the presence of 
the acridan-based substrate, was detected by a ChemiDoc Imager (Bio-Rad).  
2.11 Indirect immunofluorescence 
Cells were grown on coverslips and washed twice for 5 minutes with Phosphate Buffered 
Saline (PBS) prior to being fixed with either 1:1 methanol/acetone solution for 2 minutes 
at RT or with 4% Paraformaldehyde (PFA) for 10 minutes at RT. In case of PFA fixation, 
cells were permeabilized with 0.2% Triton X-100 for 10 minutes at RT. Coverslips were 
incubated for 1 hour in blocking solution (PBG; 0.5% BSA, 0.2% gelatin from cold water 
fish skin) and subsequently incubated with a mix of primary antibody(s) and PBG for 1 
hour at RT in a humidified chamber. Cells were washed 3 times for 5 minutes with PBG 
and later incubated with second solution containing secondary antibody(s) and PBG for 1 
hour at RT in a dark chamber to avoid the fading of the fluorochrome conjugated to the 
secondary antibody. Cells were washed twice for 5 minutes with PBG, twice for 5 minutes 
with PBS and incubated with 4'-6-Diamidino-2-phenylindole (DAPI, 1µg/ml, Sigma-
Aldrich) for 2 minutes at RT. Cells were sequentially washed with PBS and water and 
coverslips were then mounted with mowiol mounting medium (Calbiochem), which acts as 
an anti-fade agent which is capable of partially avoiding light-induced fading of the 
fluorophore. 
2.12 BrdU incorporation assay followed by immunofluorescence. 
To study DNA replication at a single cell level, cells were incubated with 5- 
bromodeoxyuridine (BrdU, Sigma-Aldrich, 10 µg/ml) for 8-24 hours. BrdU is a synthetic 
thymidine nucleoside analogue, which is incorporated into replicating DNA and can be 
detected by immunofluorescence. BrdU-pulsed cells plated on coverslips were fixed with 
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4% PFA for 10 minutes and permeabilized with 0.2% Triton X-100 for 10 minutes at RT. 
Cells were subsequently blocked with PBG for 1 hour and later incubated for 45 minutes at 
RT with a mixture containing anti-BrdU primary antibody (diluted 1:20), DNase 
(Promega, 0.1 U/µl,) and DNase buffer. Cells were then washed 3 times for 5 minutes with 
PBG and later incubated with a solution containing a secondary antibody, capable of 
recognising the anti-BrdU primary antibody, and PBG for 1 hour at RT in a dark chamber 
to avoid the fading of the fluorochrome conjugated to the secondary antibody. Cells were 
later washed twice with PBG and twice with PBS. DAPI staining was used to detect each 
nucleus and mowiol (Sigma-Aldrich) solution was used to mount coverslips. 
2.13 Resazurin cell proliferation assay 
Cultured cells with active metabolism can reduce a blue compound called resazurin (7-
hydroxy-3H-phenoxazin-3-one-10-oxide, Sigma-Aldrich), to generate a pink molecule 
named resorufin (7-Hydroxy-3H-phenoxazin-3-one), with absorbance at 570 nm. 
Resazurin reduction may originate via different oxidase enzyme systems, using NAD(P)H 
as the major electron donor. The metabolic activity of cultured cells directly correlates to 
the production of resorufin, which was quantified by absorbance spectroscopy in a Perkin 
Elmer EnVisionÔ 2104 Microplate Reader. Prior to absorbance reading, cultured cells 
plated in a 96-well plate were incubated for 2 hours with resazurin (1:10). 
2.14 Ionizing radiation 
Ionizing radiation (IR) at 20 Grays (Gy, the International System of Units of absorbed 
radiation dose, where 1 Gy is the absorption of a joule of radiation energy per kilogram of 
matter) was used to generate acute exogenous DNA damage to induce IR-dependent 
cellular senescence. IR-induces lesions including base damage, SSBs, DSBs and DNA 
cross-links. A radiation-generating machine (Faxitron X-Ray Corporation), based on a 
high-voltage X-rays generator tube, was used for cell irradiation. 
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2.15 Imaging 
Immunofluorescence images were acquired using a wide field Olympus Biosystems 
Microscope BX61 or a GE Healthcare DeltaVision Elite high-resolution fluorescence 
microscope. To allow a more accurate and high throughput signal discrimination and 
detection of co-localization events, software-based image deconvolution of DeltaVision 
acquisitions was performed in order to generate optical sections at different levels along 
the z axis of the cell. Co-localization between DDR markers and telomeres was assessed 
by ImageJ software with a customized ImageJ macro to allow 3D stack analysis. Two 
points were considered co-localizing if their respective intensities were higher than the 
threshold of their channels and if 5 pixels or more overlapped between both channels 
within the same section of the stack. Olympus wide field microscopes were used for the 
remaining imaging experiments (BrdU, Ki67 and DDR markers). Comparative 
immunofluorescence analyses were performed in parallel with identical acquisition 
parameters. 
2.16 Antibodies 
As primary antibodies, I used anti-Lamin A/C (goat, Santa Cruz sc6215, 1:1000); anti-
γH2AX (mouse, Millipore 05-636, 1:200); anti-ATM pS1981 (mouse, Rockland 200-301-
400, 1:1000; rabbit, Abcam ab2888, 1:500); anti-pS/TQ (rabbit, Cell Signalling 2851, 
1:200); anti-53BP1 (rabbit, Novus NB100-304, 1:1000; goat, Novus AF1877, 1:1000); 
anti-BrdU (mouse, Becton Dickinson 347580, 1:20), anti-Ki67 (rabbit, Abcam ab16667, 
1:50); anti-TRF2 (mouse, Millipore 05-521, 1:200); anti-FLAG (mouse, Sigma-Aldrich 
F3165, 1:500); anti-Vinculin (mouse, Sigma-Aldrich V9131, 1:2000); anti-Tubulin 
(mouse, Sigma-Aldrich T5168, 1:2000). As secondary antibodies, I used anti-Mouse or 
anti-Rabbit Alexa 488 IgG (donkey, Life Technologies, 1:400); anti-Mouse or anti-Rabbit 
Cy3 IgG (donkey, Jackson Immuno Research, 1:400), anti-Mouse, anti-Goat or anti-Rabbit 
Alexa 647 IgG (donkey, Life Technologies, 1:400). 
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2.17 Statistical analyses 
p-values below 0.05 were considered as statistically significant. T-Student's two-tailed t-
test was used for means comparisons of two independent samples whereas one-way 
ANOVA followed by the indicated post hoc test was used to compare the means of 
multiple independent samples. Chi-squared test was used for qualitative data where 
expected frequencies were compared to the observed frequencies. 
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3 RESULTS	
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3.1 Development of Target-Enrichment of small RNAs (TEsR). 
3.1.1 Overview and introduction of the method. 
In collaboration with the laboratory of Piero Carninci at the RIKEN Center for Life 
Science Technologies (Yokohama, Japan), we have developed a method that we named 
Target-Enrichment of small RNAs (TEsR), which allows the targeted sequencing of rare 
small RNAs (sRNAs) and diverse precursor and mature forms of sRNAs not easily 
detectable by current state-of-the-art sRNA sequencing methods (Nguyen et al. in press, 
2017). In order to set up this method, Quan Nguyen, a postdoctoral fellow at RIKEN, 
visited our laboratory in Milan to develop the workflow of TEsR. Later on, I visited myself 
the RIKEN laboratory in Japan to continue this collaboration and I spent there 5 weeks to 
finalize the project.  
In brief, TEsR allows the enrichment of the sRNAs of interest by generating RNA libraries 
that are hybridized to one or multiple sequence-specific biotin-labeled RNA bait(s). Non-
hybridized RNAs are washed away, while bait-hybridized RNA molecules are retained and 
sequenced.  
Compared to the current sequencing approaches, the main advantages of TEsR are: (i) it 
generates 400-30,000 fold deeper sequencing data; (ii) it allows inexpensive sequencing of 
multiple samples and target RNAs in a single run with a small sequencer such as Illumina 
MiSeq; (iii) it captures RNA lengths ranging from microRNA size to long RNA transcripts 
(shorter than 1 Kb to be suitable for Illumina sequencing); (iv) it enriches for mature 
sRNAs and their precursors and generates strand-specific sequencing reads, therefore, 
being capable of differentiating both sense and antisense RNAs; (v) it works robustly with 
small RNA inputs (as little as 10ng of RNA is enough to generate a TEsR library).  
In TEsR, linkers are ligated to each of the two ends of the full-length sRNA molecules 
(Figure 6a). In order to minimize undesired ligations, amine-blocked linkers are used to 
block 3’-ends and pre-adenylated DNA linkers to increase reactivity with 3’-end of RNA 
(Figure 7a). Moreover, to capture also the significant proportion of sRNAs that are 
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capped, as this is the case for many small nuclear RNA (snRNA), small nucleolar RNA 
(snoRNA), tRNA, and miRNA, a 5’-cap removal step before ligating the 5’-RNA linker to 
the 3’ end of sRNA is applied. In TEsR, after linkers’ ligation, all ligated sRNAs are 
amplified by PCR (Figure 7b), targeted molecules are specifically enriched by hybridizing 
with biotinylated RNA baits generated in the lab (Figure 6b, c and Figure 7c), and PCR 
products are then wash-removed from abundant and/or irrelevant RNA species. Finally, by 
the use of sequencing primers, the enriched bait-captured products are PCR-amplified and 
the final sequencing libraries are generated (Figure 6c and Figure 8). 
 
Figure 6. Overview of the Targeted Enrichment of RNAs (TEsR) method. 
(a) Small RNA ends are ligated to a RNA and a DNA linker in the 5’ and 3’ end respectively, followed by 
retrotranscription of RNAs and PCR amplification using primers on both attached linkers. (b) A starting 
DNA oligo containing the target sequence to enrich for is PCR-amplified and a T7 promoter sequence is 
incorporated. In vitro transcription using Biotin-16-dUTP allows the synthesis of biotinilated RNA baits. (c) 
Capturing of target RNAs is performed through binding of the precaptured denatured libraries to RNA baits. 
Streptavidin magnetic beads (MB) are used to trap the RNA baits. After release of libraries, targeted 
sequences are indexed by PCR with sequencing primers for final library preparation.  
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Importantly, so far, no method for targeted sequencing of sRNA was available. To address 
this need, we have developed a complete protocol (Nguyen et al. in press, 2017) and 
optimized conditions compatible for capturing and deep-sequencing a wide range of sRNA 
transcripts. We thus carefully calibrated the key capture parameters like probe 
concentration and ratios, hybridization time and temperature, and wash removal post 
hybridization. 
 
Figure 7. Profiles exemplifications for the monoadenylation of 3’ DNA linker and library and RNA 
bait generations. 
(a) Testing the production of adenylated 3’ adapter on a denaturing 20% polyacrylamide gel. ‘Linker’ lane is 
the control with template only, without adenylation; the ‘App Linker’ indicates the adenylated adapter. The 
quality of adenylated adapter product can be judged based on the percent of adenylated vs not adenylated. (b) 
The top and low panels show the bionanalyzer profiles of precaptured libraries before and after the PCR step, 
respectively. Green boxes indicate the lower Bioanalyzer marker (1) and other pre-PCR oligos (2). In 
particular, (2) -in the upper panel- shows the oligos used for ligation to RNA as well as those used for reverse 
transcription, however the contamination of undesired oligos (like adapter dimers) after PCR amplification of 
cDNA is markedly reduced as seen in (2) of the lower panel. Blue boxes show library size distributions and 
Purple boxes show the upper Bioanalyzer marker. (c) Validation of RNA products after T7 in vitro 
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transcription. RNA baits were run on a 1% agarose gel. RNase-treated baits (PCR temp) were used as a 
control, proving that the signal obtained was mainly from RNA molecules. 
 
Figure 8. Bioanalyzer profiles and schematic overview of representative final TEsR libraries. 
(a) Representative High Sensitivity Bioanalyzer profiles of final libraries of 4 different biological replicates 
(lanes 1-4). On the left, 1 -in green- represents the lower Bioanalyzer marker and 2 -in purple- shows the 
upper Bioanalyzer marker. On the right, lane number 5 shows the negative control PCR, where no template 
was used. L represents the dsDNA ladder used. (b) Single nucleotide resolution scheme of final libraries. N 
represents a given nucleotide according to the sequence of the transcriptome enriched for. X represents a 
given nucleotide according to the complete list of index sequences provided by ScriptSeq™ Index PCR 
Primers.  
 
3.1.2 Validation of the TEsR method. 
In order to validate TEsR, three different sRNAs were captured: miR29b1, Snord68 (small 
nucleolar RNA, C/D box 68) and Snord70 (small nucleolar RNA, C/D box 70) in four 
independent biological replicates (Figure 9) where total RNA samples from mouse 
embryonic fibroblasts (MEF) were used. For each TEsR experiment, simultaneous 
hybridization of three sRNA targets was carried out by simply pooling different RNA baits 
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containing the sequences of the three targets at equimolar concentrations into one 
hybridization reaction tube. For all four experiments, the enrichment obtained of the three 
sRNA targets was approximately 4 times higher than the total remaining 5,515 annotated 
mouse sRNAs, including all miRNAs, small ribosomal RNAs, snoRNAs, and snRNAs 
(Figure 9a). Importantly, a pooled read coverage of the three sRNA targets of 78% to 83% 
of the total read counts sequenced from the libraries was obtained. Conversely, in control 
standard libraries run on a sequencer with higher depth capability (HiSeq), the three 
sRNAs accounted only for approximately 0.2 % of the total reads counts (Figure 9b), thus 
demonstrating that TEsR generated a 400-fold enrichment of these three sRNA targets 
compared to standard sequencing. Moreover, we obtained a dramatic shift in detection 
ranks of the three targeted sRNAs when comparing captured to not-captured libraries 
(Figure 9 c, d), proving a more efficient performance and cost-effective results obtained 
by TEsR method, even on a Illumina MiSeq sequencer with lower sequencing depth as 
compared to HiSeq. 
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Figure 9. Evaluation of the enrichment of three sRNA targets by TEsR. 
Different probes were used for simultaneously capturing three sRNAs: miR29b1, Snord68 and Snord70. (a) 
The relative abundance of captured targets compared to all remaining not-captured sRNA in each of the 4 
captured Illumina MiSeq sequencing libraries and (b) in not-captured Illumina HiSeq sequencing of standard 
TruSeq small RNA libraries. The ranks of abundance levels for three captured small RNA targets in captured 
libraries (c) compared to in not-captured libraries (d), in two biological replicates are shown for captured and 
control libraries (CtrLib). Results by Quan Nguyen. 
  
Next, spike-in RNAs and serial dilutions of total RNA samples were used to estimate the 
correlation between final read counts and initial concentrations of the captured RNA 
molecules. Two different RNA molecules were targeted separately, each of which had 
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three different dilutions (Figure 10a). The first target was a chemically-synthesized spike-
in RNA molecule different in sequence from any well-known endogenous sRNA in mouse 
and human. The second RNA captured was the human endogenous miR29b-1. 
Importantly, a strong correlation was observed between concentrations and read count 
values for both miR29b-1 and spike-in target (R2 >0.99) demonstrating the linear range of 
the data (Figure 10a). Moreover, the reproducibility of the method was assessed by 
capturing and sequencing Snord70, Snord68 and miR29b-1 in two distinct replicates 
(Figure 10b). All captured targets were consistently placed on the regression line between 
the two replicates thus proving the reproducibility of TEsR (Figure 5b). 
 
Figure 10. Assessing reproducibility and quantitativeness of the TEsR method.  
(a) Correlations of read count per million to concentrations of each captured targets, including a spike-in and 
the endogenous miR29b RNA, each with three dilutions (0.1, 10 and 100). (b) Correlation plots of the 
abundance of small RNA from two independent TEsR experiments. Snord70, Snord68 and miR29b1 were 
the three captured targets, shown in red. Results by Quan Nguyen. 
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3.2 DICER and DROSHA-dependent telomeric RNAs are induced at 
dysfunctional telomeres.  
3.2.1 Telomere dysfunction induces the transcription of telomeric DDRNAs and their 
precursors.  
To test the potential generation of DDRNAs at endogenous damaged sites like telomeres, I 
employed Trf2 conditional knock out mouse embryonic fibroblast (MEF) cell lines (Trf2F/+ 
and Trf2F/F MEFs), which carry a Cre recombinase (Rosa26-CreERT2) inducible by 4-
hydroxytomaxifen (4OHT). I treated MEFs with 4OHT for 48 hours in order to induce the 
translocation of Cre recombinase into the nucleus. Trf2 removal leads to telomere 
dysfunction, as telomeric DNA ends are recognized as DSBs, which can be detected by 
immunofluorescence in the form of Telomere Induced Foci (TIFs) (Figure 11 and 
(Okamoto et al., 2013)).  
 
Figure 11. Induction of telomere dysfunction in Mouse Embryonic Fibroblasts (MEFs). 
MEFs of the indicated genotype were treated with 4OHT (0.6 µM) for 48 hours and subsequent 
immunofluorescence experiments were performed to stain for 53BP1 and γH2AX DDR markers. 
 
As DDRNAs are transcribed at DSBs and contain the corresponding sequence of the 
damaged genomic site, I aimed to study and monitor the expression of telomeric DDRNAs 
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(tDDRNAs) by using an RT-qPCR-based method developed to detect and quantify small 
RNAs (Figure 12). In brief, this method allows the polyadenylation of RNAs by a poly(A) 
polymerase followed by reverse transcription using oligo-dT primers. These oligo-dT 
primers contain a universal tag sequence on the 5' end, allowing amplification of small 
RNA in the real-time PCR step (Figure 12). In order to detect tDDRNAs, I designed 
primers to selectively amplify either the G-rich strand (teloG) or the C-rich strand (teloC) 
of potential tDDRNAs generated at dysfunctional telomeres. 
 
Figure 12. Detection of DDRNAs: schematic description of the amplicon synthesis. 
Small RNA is firstly polyadenilated, then retrotranscription is enabled by using a primer containing a polyT 
tail and a universal tag. Lastly, qPCR is performed using universal and specific primers on the cDNA. 
 
In order to minimize the contribution of longer telomeric RNA species, including TERRA, 
I employed a gel-extracted fraction of RNAs shorter than 40 nucleotides prior to the 
polyadenylation step in Figure 12. Upon Trf2 knock out I observed an induction of both 
teloG and teloC DDRNAs (Figure 13a), raising the possibility of the in vivo formation of 
double-stranded tDDRNA molecules. The signals detected were not due to genomic DNA 
contamination as only a low qPCR background signal was detected in the absence of 
reverse transcriptase (Figure 13b). 
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Figure 13. Deprotection of telomeres leads to increased levels of tDDRNAs in MEFs.  
(a) MEFs of the indicated genotype were treated with 4OHT (0.6 µM) for 48 hours and collected for total 
cell RNA extraction. Small RNAs were gel-extracted (< 40 nt) and used for PCR amplification (as described 
on Figure 12) to detect tDDRNAs. DDRNA levels were normalized to mir29b and Trf2F/+ + 4OHT MEFs. 
Error bars represent the s.e.m. n=3 independent experiments. *p-value<0.05, **p-value<0.01, Student’s t-
test. (b) Gel-extracted small RNA fraction (< 40 nucleotides) was used PCR amplification as in a. 
Retrotranscription reactions were performed in the presence (Reverse transcriptase +) or absence (Reverse 
transcriptase -) of the reverse transcriptase enzyme. Error bars represent s.d. of 3 technical replicates. 
 
To extend these observations to human cells, I used T19 cells, a HT1080 fibrosarcoma cell 
line expressing a doxycycline-induced FLAG-tagged dominant negative form of TRF2 
(TRF2 ΔBΔM). TRF2 ΔBΔM binds the endogenous wild type TRF2 and forms an inactive 
heterodimer, unable to bind DNA, thus blocking the accumulation of TRF2 on 
chromosome ends ultimately leading to telomere deprotection and DDR activation. The 
expression of TRF2 ΔBΔM was induced by culturing cells in the absence of doxycycline 
for 8 days. Cells expressing the TRF2 ΔBΔM mutant stained positive for FLAG-tag and 
DNA damage response in the form of 53BP1 foci (Figure 14 and (van Steensel et al., 
1998)). 
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Figure 14. Induction of telomere dysfunction in T19 human cells. 
T19 cells were treated, or not, with doxycycline. FLAG-tagged TRF2 ΔBΔM expression was detected by 
FLAG immunofluorescence staining in cells cultured without doxycycline for 8 days. Cells cultured with and 
without doxycycline for 8 days were stained for 53BP1. FLAG-tagged TRF2 ΔBΔM-expressing cells elicit 
telomere DNA damage as indicated by 53BP1 foci accumulation. 
 
Consistent with tDDRNA induction in Trf2-depleted MEFs, I observed in T19 cells both 
teloG and teloC DDRNA levels increased upon induction of telomere dysfunction (Figure 
15), suggesting a conserved mechanism for tDDRNA induction across mammalian species.  
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Figure 15. Deprotection of telomeres leads to increased levels of tDDRNAs in T19 cells. 
T19 cells were treated, or not, with doxycycline for 8 days and collected for RNA extraction. Small RNAs 
were gel-extracted (< 40 nt) and used for PCR amplification (as described on Figure 12) to detect tDDRNAs. 
DDRNA levels were normalized to mir29b and TRF2 WT T19 cells.  Error bars represent the s.e.m. n=3 
independent experiments. *p-value<0.05, Student’s t-test. 
 
To further characterize the length and sequence of tDDRNAs, I treated Trf2F/+ and Trf2F/F 
MEFs with 4OHT for 48 hours and performed TEsR, which captured and enriched for 
tDDRNAs followed by next generation sequencing as described in section 3.1. By this 
approach, I observed that telomere dysfunction induced the accumulation of small 
telomeric transcripts generated from both teloG and teloC strands, including the expected 
tDDRNA size range products (Figure 16). 
 
Figure 16. Characterization of tDDRNAs by Targeted Enrichment of RNAs (TEsR) method. 
Small RNA (<200 nucleotides) fractions were isolated from MEFs of the indicated genotype treated with 
4OHT (0.6 µM) for 48 hours, enriched for species with telomeric sequences using the TEsR method 
described on Figure 9. Bar graphs show for each read length the number of telomeric reads, either G rich or 
C rich, normalized on mir29b reads. n=3 independent experiments. Bioinformatics analysis was performed 
by Fabio Iannelli.  
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As previous work from our lab has shown DROSHA and DICER involved in DDRNA 
biogenesis on DSB generation (Francia et al., 2012, Michelini et al., 2017), I next looked 
for evidence of longer telomeric RNA species – we termed damage-induced long non-
coding RNAs (dilncRNAs) – that would serve as RNA substrates of DROSHA and DICER 
for tDDRNA production. For this purpose, I performed a strand-specific fixed-length RT-
qPCR that allows the real-time amplification and quantification of repetitive sequences, 
such as UUAGGG tandem repeats. PCR on RNA molecules shorter than 40 nucleotides 
did not generate any amplicon, ruling out the possibility of DDRNA detection by this 
approach (Figure 17a). Upon Trf2 knock out, I observed an increase of 10- to 20-fold 
telomeric dilncRNAs (tdilncRNAs) compared to control cells (Figure 17b), demonstrating 
a strong induction of telomere transcription on both strands upon telomere dysfunction. 
 
Figure 17. Deprotection of telomeres leads to increased levels of tdilncRNAs in MEFs. 
MEFs of the indicated genotype were treated with 4OHT (0.6 µM) for 48 hours and collected for total cell 
RNA extraction. (a) Gel-extracted total RNA was separated in less than 40 (<40) and more than 40 (>40) 
nucleotides. Strand-specific fixed-length RT-qPCR was used (n.d. = not detectable). Error bars represent s.d. 
of 3 technical replicates. (b) MEFs of the indicated genotype were treated with 4OHT (0.6 µM) for 48 hours 
and total cell RNA was isolated in order to perform strand-specific fixed-length RT–qPCR to detect 
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tdilncRNAs. tdilncRNA levels were normalized to Rplp0 mRNA and Trf2F/+ + 4OHT MEFs. Error bars 
represent the s.e.m. n=3 independent experiments. *p-value<0.05; ***p-value<0.001, Student’s t-test. 
 
3.2.2 DDR at dysfunctional telomeres is DROSHA and DICER dependent. 
As DDRNA biogenesis has been shown to be DROSHA and DICER dependent, I 
investigated their role in telomeric RNA processing by knocking down individually both 
endoribonucleases in Trf2F/F MEFs. I observed that DICER or DROSHA depletion fully 
abolished both teloG and teloC tDDRNAs induction upon telomere dysfunction induction 
(Figure 18).  
 
Figure 18. Drosha and Dicer are involved in tDDRNA generation. 
MEFs of the indicated genotype were simultaneously treated with 4OHT (0.6 µM) and transfected with the 
indicated siRNA for 48 hours and collected for total cell RNA extraction. Small RNA was gel-extracted (< 
40 nt) and used for PCR amplification (as described on Figure 12) to detect tDDRNAs. Since most 
microRNAs (included mir29b) are susceptible to Drosha and Dicer knock down, a spike-in RNA introduced 
in the samples prior to gel loading was used to normalize at the qPCR step. DDRNA levels were normalized 
to Trf2F/+ + 4OHT + siControl. Error bars represent the s.e.m. n=3 independent experiments. *p-value<0.05, 
Student’s t-test. 
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Furthermore, I monitored tdilncRNAs in Drosha- and Dicer-deficient Trf2F/F MEFs. Upon 
trf2 knock out, tdilncRNAs increased significantly in Drosha-depleted cells (Figure 19). 
These results are consistent with dilncRNAs being DDRNA precursors, which are 
processed by DROSHA and DICER to generate functional tDDRNAs. Dicer knockdown 
did not show a significant increase of tdilncRNA as it likely leads to the accumulation of 
small RNA intermediates too short to be detected by qPCR in this experimental setting. 
 
Figure 19. Drosha and Dicer are involved in tdilncRNA processing. 
MEFs of the indicated genotype were simultaneously treated with 4OHT (0.6 µM) and transfected with the 
indicated siRNA for 48 hours and total cell RNA was isolated in order to perform strand-specific RT–qPCR 
to detect tdilncRNAs. tdilncRNA levels were normalized to Rplp0 mRNA and Trf2F/+ + 4OHT + siControl 
MEFs. Error bars represent the s.e.m. n=3 independent experiments. *p-value<0.05; Student’s t-test. 
 
Next, I studied the impact of Drosha or Dicer knockdown in DDRNA biogenesis and its 
potential inhibition of DDR activation at dysfunctional telomeres. Consistent with the 
reported unaltered levels of γH2AX in cells exposed to ionizing radiation and depleted of 
either Drosha or Dicer (Francia et al., 2012), induction of telomere dysfunction in Trf2F/F 
MEFs followed by Drosha or Dicer depletion lead to unaltered γH2AX foci formation 
(Figure 20 b,c). I studied then the activation of the DDR apical kinase ATM at serine 1981 
(ATM pS1981) and observed that the fraction of positive cells for pATM pS1981, as well 
as the ones positive for the consensus target sequence (pS/TQ) of proteins phosphorylated 
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by PI3-like kinases including ATM, were strongly decreased upon Drosha or Dicer 
knockdown (Figure 20 b,c).  
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Figure 20. Drosha and Dicer are necessary for full DDR activation at deprotected telomeres. 
MEFs Trf2F/F were simultaneously treated with 4OHT (0.6 µM) and transfected with the indicated siRNA. 48 
hours later, cells were 4% PFA-fixed or collected for RNA extraction. (a) Representative RT-qPCR to detect 
Drosha and Dicer mRNA levels. Error bars represent the s.e.m. of 3 technical replicates. (b) Fixed cells were 
stained for the indicated DDR markers. Scale bar, 10 µm. (c) Quantification of data shown in b. Bar graphs 
show the percentage of DDR-positive cells±95% confidence interval n=3 independent experiments. ***p-
value<0.001, Chi-squared test. A cell was counted as positive if showing >3 foci. Combined results by Julio 
Aguado and Francesca Rossiello. 
 
Moreover, I observed that also in the T19 human cell system, both Dicer and Drosha 
knockdown decreased the recruitment of ATM pS1981 and pS/TQ, to dysfunctional 
telomeres, but not the formation of γH2AX foci (Figure 21).  
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Figure 21. DROSHA and DICER are necessary for full DDR activation at deprotected telomeres in 
T19 cells. 
(a) T19 cells were cultured without doxycycline for 8 days in order to express TRF2 ΔBΔM. Cells were 4% 
PFA-fixed or collected for total RNA extraction prior to a 48-hour transfection with the indicated siRNAs. 
Fixed cells were stained for the indicated DDR markers. Scale bar, 5 µm. (b) Quantification of data shown in 
a. Bar graphs show the percentage of DDR-positive cells±95% confidence interval n=3 independent 
experiments. ***p-value<0.001, Chi-squared test. A cell was counted as positive if showing >3 foci. 
 
Thus, the recruitment of DDR factors downstream of γH2AX, including ATM pS1981 and 
pS/TQ, to dysfunctional telomeres requires Dicer and Drosha endoribonucleases both in 
human and mouse cells.  
 
3.2.3 Telomeric antisense oligonucleotides prevent DDR activation at dysfunctional 
telomeres. 
As tDDRNAs at dysfunctional telomeres have a crucial role in DDR signalling, we aimed 
to inhibit them with the use of antisense oligonucleotides (ASOs). Inhibitory ASOs are 
commonly employed to block the functions of RNA molecules (McClorey and Wood, 
2015) by steric hindrance. Thus, we designed ASOs to either bind the G-rich (named anti-
teloG) or C-rich (named anti-teloC) strand of tDDRNAs and tdilncRNAs and an ASO with 
an unrelated control sequence. We then transfected ASOs in Trf2F/F MEFs treated with 
4OHT for 48 hours to induce telomere dysfunction. Most importantly, both anti-teloG and 
anti-teloC ASOs, but not the control one, reduced the number of 53BP1 and pS/TQ foci at 
dysfunctional telomeres (Figure 22). On the contrary, and in agreement with the Dicer and 
Drosha knockdown experiments, we observed unaltered γH2AX foci formation (Figure 
22).  
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Figure 22. Telomeric ASOs inhibit DDR activation at dysfunctional telomeres. 
(a) MEFs Trf2F/F were treated, or not, with 4OHT (0.6 µM) and transfected with the indicated ASO. Fixed 
cells were stained for the indicated DDR markers. Scale bar, 10 µm. (b) Quantification of data shown in a. 
Dot plots show the number of DDR foci per cell. Lines indicate the mean ±s.e.m. n=3 independent 
experiments. **p-value<0.01; ***p-value<0.001, one-way ANOVA with multiple-comparison post-
hoc corrections. Results by Francesca Rossiello.  
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3.3 A link between tDDRNAs and telomere-driven cellular senescence. 
3.3.1 Replicative senescent cells undergo telomeric DDRNA accumulation 
Progressive telomere attrition occurs as proliferating mortal human cells undergo 
population doublings, ultimately leading to exposed free double-stranded chromosome 
DNA ends (d'Adda di Fagagna et al., 2003). This event, triggers a persistent and 
irreparable telomeric DDR (Fumagalli et al., 2012), which leads to senescence induction. 
In order to test whether tDDRNA production indeed triggers replicative senescence, I 
purified RNA from early passage (population doubling 32) and late passage (population 
doubling 89) BJ cells and observed an induction of both teloG and teloC DDRNAs 
(Figure 23), consistent with the reported accumulation of DNA damage at the telomeres. 
 
Figure 23. tDDRNAs are induced in replicative senescent cells. 
Small RNA was gel-extracted (< 40 nt) and used for PCR amplification (as described on Figure 12) to detect 
tDDRNAs. Error bars represent the s.e.m. n=3 independent experiments. tDDRNA levels were normalized to 
mir29b and to Early passage BJ cells. 
 
3.3.2 A role of tDDRNAs in IR-induced senescence 
As IR-induced senescence is a result of the inability of cells to repair some genomic sites 
of the genome, including telomeres (Fumagalli et al., 2012), I aimed to set up an 
experimental design where quiescent early passage BJ cells were irradiated (20 Gy) and 
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left to recover for four weeks prior to RNA extraction. Consistent with the reported 
accumulation of DNA damage at the telomeres, I could detect an induction of DDRNAs 
upon IR-induced senescent cells as compared to BJ control cells (Figure 24).  
 
Figure 24. tDDRNAs accumulate in IR-induced senescent cells. 
Small RNA was gel-extracted (< 40 nt) and used for PCR amplification (as described on Figure 12) to detect 
tDDRNAs. Error bars represent the s.e.m. n=3 independent experiments. tDDRNA levels were normalized to 
mir29b and BJ control non-irradiated cells. 
Next, I aimed to monitor senescence markers by directly inhibiting tDDRNA and 
tdilncRNA functions through ASO delivery. To do so, cells were transfected at 50% 
confluency and irradiated (at 20 Gy) once they became fully confluent. Four weeks after 
irradiation I tested for senescence markers.  
p21 and p16 mRNA levels, markers often expressed in senescence, and SASP genes IL-6, 
IL-8 and IL-1A were all induced four weeks after irradiation (Figure 25). Interestingly, 
p16 and p21 mRNA levels decreased upon telomeric ASO treatment (Figure 25a, b) 
whereas SASP genes remained unaltered (Figure 25c); suggesting a tDDRNA/tdilncRNA-
independent mechanism for SASP production. 
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Figure 25. Telomeric ASO treatment suppresses p21 and p16 induction of IR-induced cells while 
maintaining SASP gene expression levels.  
RT-qPCR analysis of p21 (a), p16 (b) and SASP (IL-8, IL-1A and IL-6) (c) mRNA levels of IR-induced BJ 
cells. Rplp0 (RPP0) mRNA was used as normalizer. n=2 independent experiments. Error bars represent the 
s.e.m. 
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3.4 The role of tDDRNAs at progerin-driven telomere dysfunction in 
Hutchinson–Gilford Progeria Syndrome. 
3.4.1 Progerin expression induces the transcription of telomeric DDRNAs and their 
precursors. 
To investigate the potential generation of tDDRNAs and study their role in an amenable 
human cell model of HGPS, I expressed wild type or the HGPS mutant form of lamin A 
gene (known as progerin) through retroviral delivery in normal human skin fibroblasts (BJ; 
Figure 26a) – this is a relevant cell model as skin abnormalities are one of the major 
HGPS phenotypes. As progerin expression has been reported to induce telomere 
dysfunction, I monitored tDDRNAs expression and indeed I discovered increased levels of 
both teloG and teloC DDRNAs upon progerin expression (Figure 26b).  
 
Figure 26. Progerin expression leads to increased levels of tDDRNAs. 
(a) Western blot analysis shows lamin A/C and progerin expression in wild type normal human skin 
fibroblasts and retrovirally-transduced Lamin A-expressing and Progerin-expressing cells. Tubulin was used 
as loading control. (b) Small RNA was gel-extracted (< 40 nt) and used for PCR amplification (as described 
on Figure 12) to detect tDDRNAs. DDRNA levels were normalized to mir17 and Lamin A control cells. 
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I next measured tdilncRNAs expression levels upon progerin expression and observed a 3- 
to 5-fold increase of both telomere strands as compared to control-cells levels (Figure 27). 
Induction of tDDRNAs and their precursors are consistent with increased telomeric DDR 
activation as previously reported (Benson et al., 2010). 
 
Figure 27. Progerin expression leads to increased levels of tdilncRNAs. 
Total cell RNA was isolated and used for strand-specific RT-qPCR to detect tdilncRNAs. tdilncRNA levels 
were normalized to Rplp0 mRNA and Lamin A control cells. Error bars represent the s.e.m. n=3 independent 
experiments.  
 
3.4.2 Progerin expression reduces cell proliferation and induces SASP expression. 
Furthermore, progerin-expressing cells showed a decrease in BrdU incorporation and in 
the percentage of Ki67-positive cells, both readouts of cell proliferation (Figure 28a) 
associated with an induction of expression of the senescence-associated secretory 
phenotype (SASP) genes interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-1A (IL-
1A) (Figure 28b), consistent with the reported senescence induction phenotype. 
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Figure 28. Progerin expression reduces cell proliferation and induces SASP expression. 
(a) Bar graphs show the percentage of BrdU and Ki67 positive cells ± 95% confidence interval. At least 100 
cells were counted for each condition. n=3 independent experiments. (b) RT-qPCR analysis of the 
senescence-associated secretory phenotype (SASP) genes interleukin-6 (IL-6), interleukin-8 (IL-8) and 
interleukin-1A (IL-1A) in BJ cells. Values are normalized to 1 on Lamin A overexpressing controls. 
 
3.4.3 Telomeric antisense oligonucleotides reduce progerin-driven telomeric DNA 
damage and improve the proliferation of progerin-expressing cells. 
I next tested whether progerin-induced DDR at telomeres could be modulated by the direct 
inhibition of tDDRNA and tdilncRNA functions through ASO delivery (as shown in 
Figure 22). I then transfected ASOs in BJ cells and expressed progerin or Lamin A 
through retroviral delivery. After 8 days, cells were stained for TRF2 and 53BP1 to look 
for DDR at the telomeres (Figure 29a). As expected, progerin expression induced the 
accumulation of TIFs as compared to Lamin A expressing cells (Figure 29b and (Benson 
et al., 2010)). Most importantly, upon progerin expression, both anti-teloG and anti-teloC, 
but not the control ASO, significantly reduced the TIFs to the levels of LaminA expressing 
control cells (Figure 29b).  
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Figure 29. Telomeric ASOs inhibit DDR activation at progerin-driven dysfunctional telomeres. 
(a) BJ cells were transfected with telomeric or control ASOs and induced the expression of either progerin or 
Lamin A through retroviral delivery for 8 days. Cells were thereafter collected for RNA and protein 
extractions or fixed for staining.  (b) Cells were stained for 53BP1 and TRF2 and set for quantification of 
telomere dysfunction-induced foci (TIFs) as determined by the co-localization of 53BP1 and TRF2. Co-
localization was assessed by ImageJ software with a customized ImageJ macro to allow 3D stack analysis. 
As stated in material and methods, two points were considered co-localizing if their respective intensities 
were higher than the threshold of their channels and if 5 pixels or more overlapped between both channels 
within the same section of the stack. **p-value<0.01; one-way ANOVA with multiple-comparison post-
hoc corrections. n=3 independent experiments. 
 
Importantly, non-telomeric DDR foci remained unaffected upon telomeric or control ASOs 
(Figure 30). 
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Figure 30. Telomeric ASO treatment has no effect in non-telomeric DDR foci. 
BJ cells were transfected with the indicated ASOs and induced the expression of either progerin or Lamin A 
through retroviral delivery for 8 days. Cells were thereafter stained for 53BP1 and TRF2. Quantification was 
performed by subtracting the TIFs as determined by the co-localization of 53BP1 and TRF2 to the overall 
53BP1 foci detected. **p-value<0.01; one-way ANOVA with multiple-comparison post-hoc corrections. 
 
Next, I used the experimental set up in which BJ cells expressing progerin or Lamin A 
through retroviral delivery were transfected with ASOs to test their proliferation. After 8 
days of infection and selection, I pulsed cells with BrdU for 8 hours and stained for both 
BrdU and Ki67. Excitingly, both anti-teloG and anti-teloC, but not control ASO, restored 
proliferation rates in progerin-expressing cells (as independently measured by BrdU and 
Ki67) to the levels of control cells (Figure 31). 
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Figure 31. Telomeric ASOs improve the proliferation of progerin-expressing cells.  
(a) BJ cells were transfected with the indicated ASOs and induced the expression of either progerin or Lamin 
A through retroviral delivery. After 8 days cells were pulsed with BrdU for 8 hours and stained for BrdU 
(green) and Ki67 (red). (b) Quantification of stainings shown in a. Bar graphs show the percentage of BrdU 
and Ki67-positive cells ± 95% confidence interval. **p-value<0.01, Chi-squared test. n=3 independent 
experiments. At least 300 cells were counted for each condition.  
 
ASO treatments leaves Lamin A and progerin protein levels unaltered (Figure 32).  
 85 
 
Figure 32. Lamin A and progerin protein levels remain unaltered upon telomeric ASO treatment.   
BJ cells were transfected with the indicated ASOs and induced the expression of either progerin or Lamin A 
through retroviral delivery for 8 days. Representative western blot analysis shows Lamin A and Progerin 
expression in BJ cells transfected with the indicated ASO. Tubulin was used as loading control.  
 
In parallel, we observed no obvious change in proliferation rates in Lamin A-expressing 
cells treated in the same way (Figure 33), suggesting a telomere-specific role of our ASOs 
in preventing proliferation inhibition mediated by tDDRNAs and tdilncRNAs induced 
upon progerin expression. 
 
Figure 33. Unaltered proliferation rates in Lamin A-expressing cells upon ASO treatment.  
Quantification of BrdU and Ki67 positive cells in Lamin A-transduced BJ cells transfected with the indicated 
ASO. 8 days after retroviral delivery, cells were pulsed with BrdU for 8 hours and subsequenty stained for 
BrdU and Ki67. Bar graphs show the percentage of BrdU and Ki67 positive cells ± 95% confidence interval. 
At least 100 cells were counted for each condition.  
 
Unexpectedly, telomeric ASO treatment in progerin-expressing cells left unaltered SASP 
gene expression levels (Figure 34), suggesting a tDDRNA-independent and likely DDR-
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independent mechanism for SASP control, and consistent with the results obtained in IR-
induced senescent cells. 
 
Figure 34. SASP mRNA levels are unaltered upon ASO treatment upon progerin expression. 
RT-qPCR analysis of SASP (IL-8, IL-1A and IL-6) mRNA levels progerin-expressing BJ cells. Rplp0 
(RPP0) mRNA and Lamin A control cells were used as normalizers. n=2 independent experiments. Error 
bars represent the s.e.m. 
 
Lastly, I monitored the nuclear shape of progerin-expressing cells upon telomeric ASO 
treatment. In order to do so, I measured the circularity index of the nuclei tested (with a 
value of 1 indicating a perfect circle and as the value approaches 0, it indicates an 
increasingly elongated shape). Consistent with previous reports, progerin expression lead 
to a decrease of circularity compared to Lamin A expressing cells (Figure 35). More 
interestingly, the nuclear shape abnormalities driven by progerin remained unaltered upon 
ASO treatment (Figure 35).  
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Figure 35. Progerin-driven nuclear shape abnormalities are unaltered upon ASO treatment. 
(a) BJ cells were transfected with the indicated ASOs and induced the expression of either progerin or Lamin 
A through retroviral delivery. After 8 days, cells were stained for Lamin A/C (green). (b) Quantification of 
stainings shown in a. Each point in the scatter plot shows the circularity index of a nucleus. ***p-value 
<0.001, one-way ANOVA with multiple-comparison post-hoc corrections. n=1 
 
3.4.4 Human primary HGPS cells accumulate tDDRNAs and their inhibition improves 
their proliferation. 
To further test the role of telomeric transcripts in progerin-driven pathology, I used HGPS 
patient-derived fibroblasts; which better resembles the human pathology of progeria and 
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whose progerin protein expression levels, as opposed to the overexpression of progerin in 
BJ fibroblasts, are comparable to Lamin A and Lamin C proteins (Goldman et al., 2004).  
I therefore transfected human primary HGPS fibroblasts with ASOs to test whether 
tDDRNA and tdilncRNAs inhibition modulates cell proliferation. To do so, I treated early-
passage HGPS fibroblasts with either telomeric or control ASOs and monitored their 
growth by a resazurin-based cell viability assay (Figure 36). Importantly, to maintain a 
constant ASO concentration of 20 nM, every time cells became confluent I split and re-
treated them until cell proliferation ceased. 
 
Figure 36. Telomeric ASO treatment improves proliferation rates by slowing down the growth decline 
of human primary HGPS fibroblasts. 
Growth curve (normalised to day 0) of human primary HGPS cells treated or not with ASOs. Cell growth 
was monitored for 11 days until cells fully arrested their proliferation. n=1 experiment. Error bars of 
technical replicates represent the s.d. 
 
Consistent with the reported growth decline phenotype, HGPS-cultured fibroblasts 
underwent a rapid growth deceleration in just a few days. Importantly, telomeric ASO 
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treatment moderately improved the proliferation rate of HGPS fibroblasts (Figure 36), 
consistent with the upregulation of both G-rich and C-rich tDDRNAs at the time points 
tested (Figure 37). 
 
Figure 37. tDDRNA induction correlates with growth decline in human primary HGPS fibroblasts. 
Mock-treated HGPS fibroblasts small RNA samples from HGPS ASO growth curves was gel-extracted (< 40 
nt) and used for PCR amplification (as described on Figure 12) to detect tDDRNAs. n=1 experiment 
tDDRNA levels were normalized to mir17 and HGPS cells (day 3). Error bars of technical replicates 
represent the s.d. 
 
Notably, this telomeric ASO-driven growth amelioration was accompanied by a decrease 
of p21 mRNA expression at late-passage HGPS cells (Figure 38a). In addition, and 
consistent with the results obtained in progerin-overexpressing BJ cells, ASO treatments 
left unaltered progerin mRNA levels (Figure 38b). 
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Figure 38. Telomeric ASO treatment partially prevents the induction of p21 mRNA in primary HGPS 
cells 
RT-qPCR analysis of the p21 (a) and progerin (b) mRNA levels of human primary HGPS fibroblasts at 
different time points after ASO transfection. BJ cells RNA was used as negative control for progerin 
detection. Rplp0 (RPP0) mRNA was used as normalizer. n.d. = not detectable. n=1 experiment Error bars of 
technical replicates represent the s.d. 
 
3.4.5 tDDRNAs and tdilncRNAs accumulate in a progeric inducible skin mouse model. 
To validate the efficacy of our telomeric ASOs in vivo in a relevant HGPS animal model, 
in collaboration with the laboratory of Maria Eriksson at Karolinska Institutet (Sweden), 
we used an inducible skin mouse model derived from the breeding of K5tTA mice6 with 
mice expressing either human Lamin A gene or the most common HGPS mutation 
(1824C>T) under tet control. These resulting mice inducibly express human lamin A or 
progerin in epidermal keratinocytes (Sagelius et al., 2008). I therefore extracted RNA from 
skin tissue of control and HGPS mice at postnatal day 6 to monitor for tDDRNAs and 
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tdilncRNAs and observed increased teloG and teloC levels of both telomere transcripts in 
HGPS mice (Figure 39).  
 
Figure 39. Accumulation of tDDRNAs and tdilncRNAs in a progeric inducible skin mouse model. 
(a) Skin from Wild type (WT) and mutant HGPS mice was collected and total cell RNA extraction was 
performed. Small RNA was gel-extracted (< 40 nt) and used for PCR amplification (as described in Figure 
12) to detect tDDRNAs. n=3 independent experiments. tDDRNA levels were normalized to mir17 and to the 
cells from skin of WT mice. (b) Total cell RNA extracted as in a was used as starting material to perform 
strand-specific RT–qPCR to detect tdilncRNAs. tdilncRNA levels were normalized to Rplp0 mRNA and to 
the cells from skin of WT mice. n=3 independent experiments. 
 
3.4.6 Progerin-expressing mice treated with telomeric antisense oligonucleotides live 
longer. 
To monitor lifespan in the HGPS skin mouse model, pregnant mice were injected with 
both anti-teloG and anti-teloC ASOs (15 mg/kg) or phosphate buffered saline (PBS) as 
control at embryonic day 17. After birth, new-born mice were injected intraperitoneally 
once every three days starting at postnatal day 2 (Figure 40a). As previously reported, 
progerin-expressing mice had a dramatically shorter lifespan compared to wild types 
(Figure 40b and (Sagelius et al., 2008)). Strikingly however, progerin-expressing mice 
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treated with anti-teloG ASO lived significantly longer than untreated controls (Figure 40b) 
while wild type mice did not show any effect in survival when injected with anti-teloG. 
Interestingly, anti-teloC ASO treatment left unaltered the lifespan of progerin-expressing 
mice (Figure 40b). Further studies will likely clarify the discrepancies observed between 
the effects of both telomeric ASOs in lifespan extension.  
 
 
Figure 40. Progerin-expressing mice treated with telomeric ASOs live longer.  
(a) Scheme of the experimental design set for ASO delivery in the HGPS skin mouse model. (b) Kaplan-
Meier curve of wild type mice treated with vehicle (n=16, yellow), anti-teloG (n=20, blue) or anti-teloC 
ASOs (n=10, green); and progerin-expressing mice treated with vehicle (n=7, black), anti-teloG (n=13, 
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purple) or anti-teloC ASOs (n=7, red). Mice were injected intraperitoneally with 15 mg/kg of telomeric ASO. 
**p-value<0.01. Kaplan-Meier survival analysis. This experiment was performed in collaboration with Maria 
Eriksson at the Karolinska Institutet (Sweden).  
 
Altogether these results demonstrate that sequence-specific targeting of tDDRNAs and 
tdilncRNAs by ASOs reduces the aging phenotype, such as cell proliferation defects, 
caused by progerin in cultured cells and in a HGPS animal model leading to lifespan 
extension. 
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4 DISCUSSION	
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4.1 The role of telomere transcription induced by telomere dysfunction. 
4.1.1 A link between RNA and the DNA damage response. 
It has been known for decades that RNA pol II shows high affinity for DNA ends (Dynan 
and Burgess, 1981); however, this notion had not been yet linked to any relevant biological 
function. Recently, our lab has demonstrated that transcriptionally active RNA pol II is 
recruited to DSBs, a mechanism facilitated by its interaction with the MRN complex 
(Michelini et al., 2017). According to our results, when a DSB arises, RNA pol II is 
recruited at the site of damage resulting in the generation of RNA transcripts (named 
dilncRNAs) resulting from the transcription from and toward the DSB site. In addition, 
DROSHA and DICER process paired dilncRNAs and generate DDRNAs, which in turn 
bind to their complementary unprocessed dilncRNA (Figure 41)(Michelini et al., 2017). 
 
Adapted from (Michelini et al., 2017) 
Figure 41. dilncRNAs orchestrate the DDR by interacting with DDRNAs at DSBs. 
Upon DSB generation, the MRN complex recruits RNA pol II at the site of damage triggering a bidirectional 
synthesis of dilncRNAs from and towards the DSB. DROSHA and DICER endoribonucleases process the 
long double-stranded RNAs, likely formed by the outcome of paired or folded dilncRNAs, generating 
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DDRNAs that ultimately pair with unprocessed single-stranded dilncRNAs. Together, they allow the 
recruitment of 53BP1 leading to the formation of the DDR focus. 
This DDRNA-driven mechanism which favours the secondary recruitment of DDR factors 
and therefore a full DDR activation, although not yet fully understood, is known to allow 
the recruitment of 53BP1 to DSBs by binding to DDRNAs (Figure 41) in a manner 
dependent on its tudor domain (Michelini et al., 2017). 
4.1.2 Telomere transcription upon telomere dysfunction. 
In line with the above-mentioned findings (section 4.1.1), Trf2-depleted MEFs (Trf2F/F 
MEFs treated with 4OHT for 48 hours), which undergo telomere dysfunction, are actively 
transcribed and generate double-stranded telomeric DDRNAs (Figures 13 and 16) and 
their precursor dilncRNAs (Figure 17). In addition, T19 human cells expressing the 
dominant negative form of TRF2, TRF2 ΔBΔM, recapitulate the tDDRNAs induction 
observed in mouse cells undergoing telomere dysfunction (Figure 15). Although PCR 
detection of a UUAGGG-tandem repeat containing RNA aimed to quantify telomeric G-
rich dilncRNAs may also amplify the telomere transcript TERRA (Azzalin et al., 2007, 
Schoeftner and Blasco, 2008), C-rich telomere CCCUAA-repeat RNAs -transcripts arising 
at chromosome ends in the direction towards the centromere- have not been yet 
functionally characterized in mammals. Moreover, the upregulation of telomeric dilncRNA 
transcription induced by the removal of TRF2 and leading to DDR activation at telomeres 
is likely independent from TERRA transcription. This is supported by the fact that TERRA 
upregulation is not dependent on DNA damage signalling caused by TRF2 removal but 
rather caused by the absence of TRF2’s homodimerization domain, which serves as a 
repressive mark for TERRA transcription (Porro et al., 2014). Furthermore, depletion of 
the telomeric proteins Rap1 or Taz1 (homologs of the mammalian proteins RAP1 and 
TRF1/2, respectively) in Schizosaccharomyces pombe strains have also been demonstrated 
to induce C-rich telomeric transcripts (Bah et al., 2012, Greenwood and Cooper, 2012), 
indicating an evolutionarily conserved increase of telomere transcription upon induction of 
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telomere dysfunction. These results are in agreement with RNA pol II recruitment at DSBs 
sites in Schizosaccharomyces pombe (Ohle et al., 2016), and with the reported enriched 
RNA pol II occupancy at telomeres upon induction of telomere dysfunction in human cells 
(Porro et al., 2014). The precise tDDRNA-dependent mechanism by which the DDR 
proteins are recruited to dysfunctional telomeres remains unclear, although previous 
reports suggest the involvement of 53BP1 in this process, as it has the ability to associate 
to RNA through its tudor domain (Pryde et al., 2005, Michelini et al., 2017). 
The fact that tDDRNAs’ biogenesis inhibition by DROSHA and DICER depletion and that 
sequence-specific ASOs against tDDRNAs and tdilncRNAs reduce DDR activation at 
telomeres (Figures 20 and 21; 22 and 29, respectively) suggests that tDDRNAs and 
tdilncRNAs act in a sequence-specific manner ultimately allowing DDR signalling, 
consistent with previous reports that show comparable evidence at other genomic regions 
(Francia et al., 2012, Michelini et al., 2017).  
  
 98 
4.2 Implications of tDDRNAs inhibition in cellular senescence. 
The ability to detect tDDRNAs and their precursor tdilncRNAs and to inhibit telomeric 
transcripts by ASO delivery may have important implications in telomere-driven biological 
processes such as cellular senescence and aging (Jeyapalan et al., 2007, Herbig et al., 2006, 
Fumagalli et al., 2012, Hewitt et al., 2012, Waaijer et al., 2016) and in pathological 
conditions such as cancer and other telomere-driven medical conditions (also known as 
telomere syndromes) (Armanios and Blackburn, 2012). 
Senescence induced by either critically short telomeres (replicative senescence) or 
irreparable telomeres after irradiation (IR-induced senescence) consistently induced the 
expression of tDDRNAs (Figures 23 and 24, respectively), indicating a role of tDDRNAs 
as potential biomarkers of DDR activation at dysfunctional telomeres in senescence. 
ASO delivery in IR-induced senescent fibroblasts reduced the expression levels of p16 and 
p21 (Figure 25a, b), both markers known to establish and maintain the growth arrest that 
is typical of senescence (Jackson and Pereira-Smith, 2006, Campisi and d'Adda di 
Fagagna, 2007), indicating a potential role for tDDRNAs to allow cell growth arrest by 
controlling the ATM-p53-p21 and p16-pRB pathways. Interestingly, the expression of the 
SASP genes IL-6, IL-8 and IL-1A upon telomeric ASO treatment remains unaltered 
(Figure 25c), suggesting a tDDRNA/tdilncRNA-independent mechanism for SASP 
production.  
Notably, it has recently been demonstrated that chromatin fragments leak out from the 
nuclei to the cytoplasm in primary human cells during senescence (Ivanov et al., 2013, 
Dou et al., 2015, Campisi, 2013), a phenomenon known to occur as a result of the loss of 
nuclear lamina protein lamin B1 (Shah et al., 2013, Shimi et al., 2011, Freund et al., 2012), 
which ultimately leads to compromised nuclear envelope integrity. However, the 
functional significance of these senescence-associated cytoplasmic chromatin fragments 
(CCFs) had remained elusive. More recently, several independent laboratories have 
demonstrated that CCFs activate the cGAS–STING pathway (Dou et al., 2017, Gluck et 
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al., 2017, Yang et al., 2017), an innate cytosolic DNA-sensing pathway which plays 
essential roles in preventing microbial infection and in triggering inflammation (Ishikawa 
et al., 2009, Barber, 2015, Ishikawa and Barber, 2008). Interestingly, these recent findings 
support the notion that the activation of cGAS–STING through CCFs’ sensing promotes 
SASP production, as depletion of either cGAS or STING in human senescent cells fully 
abrogates SASP gene expression without affecting senescence maintenance, as measured 
by p16 and lamin B1 markers and SA-β-gal activity (Dou et al., 2017). Furthermore, 
overexpression of lamin B1 in senescent cells has little effect on the induction of γH2AX 
and p-ATM S1981, but significantly abrogates the formation of CCFs and the SASP gene 
expression (Dou et al., 2017). On the other hand, suppression of cGAS or STING upon 
senescence induction in human primary fibroblasts had no effect in DDR signaling as 
measured by pATM S1981 and γH2AX proteins levels (Dou et al., 2017). Although further 
studies have to be performed in order to elucidate the precise mechanism of SASP 
activation, the apparent DDR-independent mechanism by which CCFs induce SASP 
expression in senescence could explain why telomeric transripts’ inhibition by ASO 
delivery had no apparent effect on IL-6, IL-8 and IL-1A mRNA expression in IR-induced 
senescent cells (Figure 25c). In line with these findings, confirmation of unaltered Lamin 
B1 levels upon telomeric transcripts’ inhibition by ASO delivery in senescent cells may 
provide an explanation of why SASP levels are not affected, because unchanged low levels 
of Lamin B1 would lead to a persistent compromised integrity of the nuclear envelope 
(Shah et al., 2013, Shimi et al., 2011, Freund et al., 2012).  
Although SASP expression is reported to partially rely on persistent DDR signaling 
(Rodier et al., 2009, Fumagalli and d'Adda di Fagagna, 2009), to what extent telomeric 
DDR is involved in this process is still unclear. A way to address this would require for 
instance ATM inhibition, as it would likely abrogate SASP production, in the same setup 
we used to test ASO treatments. Impaired SASP expression upon ATM inhibition but 
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unaltered SASP levels upon telomeric ASO treatment would suggest a telomeric DDR-
independent mechanism by which SASP is generated in senescent cells.  
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4.3 Inhibition of progerin-driven telomere DDR signaling ameliorates 
the aging phenotype. 
HGPS and other premature aging syndromes provide an opportunity to understand the 
mechanisms that drive aging. In agreement with the previously reported progerin-driven 
telomere dysfunction (Benson et al., 2010), overexpression of progerin in human skin 
fibroblasts leads to an increase of Telomere Induced Foci (TIF), as monitored by the co-
localization events between TRF2 and 53BP1 (Figure 29). This increase of DDR 
signalling at the telomeres is consistent with the induction of tDDRNAs and their precursor 
tdilncRNA (Figures 26 and 27, respectively) as compared to control Lamin A-expressing 
cells. 
Although no reports studying HGPS patient-derived cells have directly reported telomere 
dysfunction, these cells have been shown to undergo accelerated telomere shortening 
(Decker et al., 2009). Interestingly, passaging in culture of human primary HGPS 
fibroblasts throughout several population doublings shows a progressive accumulation of 
tDDRNAs’ expression (Figure 37) and a gradual growth rate loss (Figure 36) associated 
with an increase of p21 mRNA level (Figure 38 and 42), altogether suggesting an increase 
of DDR activation at telomeres. However, further studies to monitor the co-localization 
events between DDR and telomere proteins are needed in order to confirm the potential 
progressive accumulation of progerin-driven dysfunctional telomeres in HGPS patient-
derived fibroblasts. 
The treatment with telomeric ASOs is able to specifically inhibit progerin-induced 
tDDRNAs and tdilncRNAs thus preventing DDR activation at dysfunctional telomeres 
(Figure 29), without affecting the signalling of DNA damage at other genomic regions 
(Figure 30). More excitingly, telomeric ASO treatment allows to rescue the proliferative 
capacity of progerin-overexpressing fibroblasts as monitored by Ki67 and BrdU positive 
cells (Figure 31), suggesting a role of tDDRNAs in regulating cell growth by controlling 
the signalling of progerin-induced telomere dysfunction (Figure 42). In line with these 
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observations, telomeric ASO treatment in human primary HGPS fibroblasts slows down 
their growth decline (Figure 36), further indicating a role of telomere dysfunction also in 
patient-derived HGPS cells. This telomeric ASO-driven improved proliferation is 
concomitant with a reduction of p21 gene expression (Figure 38), a decrease consistent to 
what is observed in IR-induced senescent cells (Figure 25a). Overall, these results 
strongly indicate a role of progerin-induced tDDRNAs and tdilncRNAs in allowing the 
activation of DDR at the telomeres that ultimately leads to a growth arrest by activating the 
ATM-p53-p21 pathway (Figure 42).  
 
Figure 42. Model of progerin-driven telomere dysfunction: a major cause of growth decline. 
Progerin expression causes accumulation of dysfunctional telomeres, which in turns leads to the induction of 
telomere transcripts ultimately allowing the full DDR activation at telomeres. Telomeric DDR induces p21 
upregulation inducing cell growth arrest.  Independently of telomere dysfunction, progerin induces SASP, 
likely due to the increase of cytoplasmic chromatin fragments induced as a consequence of nuclear shape 
abnormalities.  
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Interestingly, and consistent with IR-induced senescent cells, the expression of the SASP 
genes IL-6, IL-8 and IL-1A upon telomeric ASO treatment in progerin-expressing 
fibroblasts remains unaltered (Figure 34), suggesting a tDDRNA/tdilncRNAs-independent 
mechanism for SASP production as hypothesized on section 4.2 a process likely dependent 
on the cGAS–STING pathway. Consistent with the unaltered expression of SASP genes, 
progerin-driven nuclear shape abnormalities remained also unaffected upon telomeric ASO 
treatment (Figure 35). Further studies likely involving cGAS, STING or ATM depletion 
have to be performed in order to unravel the precise mechanism of progerin-induced SASP 
genes in HGPS. 
Consistent with the progerin-driven tDDRNA and tdilncRNA induction observed in vitro, 
quantification of telomeric transcripts in an HGPS skin mouse model shows an increase of 
both tDDRNAs and their precursors as compared to wild type mice (Figure 39). The 
consistent induction of tDDRNAs and tdilncRNAs in vitro and in vivo in different HGPS 
models strongly indicate a role of telomere dysfunction in HGPS pathology. Finally, the 
observed in vitro telomeric ASO-driven amelioration of cell proliferation both in progerin-
overexpressing human fibroblasts and in patient-derived cells is consistent with the 
increase of lifespan in the HGPS skin mouse model (Figure 40). Although further analyses 
need to be performed in order to understand the mechanism by which telomeric ASOs 
modulate cell proliferation at a single-cell level in vivo, this initial set of results are 
promising and suggest a potential use of telomeric ASOs as a therapeutic option worth 
exploring for HGPS patients. 
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4.4 Hutchinson-Gilford progeria syndrome: in search for a treatment. 
Although several drugs have proven to show beneficial effects on a subset of progerin-
driven features, aiming however only to control complications such as cardiovascular 
problems, no specific treatment is yet available to cure HGPS. In the recent years, several 
clinical trials have been carried out on HGPS children (Gordon et al., 2012, Rehman et al., 
2015). Although there is still no approved drug for treatment of HGPS by the Food and 
Drug Administration (FDA), these trials are offering a promising future for HGPS patients 
(Rehman et al., 2015). However, the therapeutic strategies proposed so far, which include 
mTOR inhibitors (Cao et al., 2011) or farnesyltransferase inhibitors (FTIs, compounds that 
prevent the farnesylation of prelamin A) (Gordon et al., 2012) target cellular pathways 
important for the normal cell activity and their inhibition have severe toxic effects 
(Rehman et al., 2015). Differently, the use of an inhibitor of tDDRNAs allows the specific 
prevention of telomeric DDR, without affecting the cell proficiency in signalling and 
repairing DNA damage at other genomic locations. 
ASOs have already been successfully used as effective FDA-approved drugs to treat 
different diseases (Stein and Castanotto, 2017, Wan and Dreyfuss, 2017). Furthermore, 
ASO-based approaches that correct aberrant LMNA splicing have already proven effective 
in a HGPS mouse model (Lee et al., 2016, Osorio et al., 2011), thus validating ASO-based 
approaches also in HGPS. However, the design and use of these splicing-correcting ASOs 
is restricted to individual HGPS mutations, since the disease can arise as a result of 
different LMNA mutations (De Sandre-Giovannoli et al., 2003, Eriksson et al., 2003, 
Moulson et al., 2007, Reunert et al., 2012, DeBoy et al., 2017, Bar et al., 2017). In 
contrast, a telomeric ASO approach has the potential to benefit any HGPS patient 
regardless of the genetic mutation, and even different progeric diseases, provided they are 
associated with telomeric DDR. Examples include atypical progeroid syndromes, 
autosomal recessive restrictive dermopathy and Nestor–Guillermo progeria syndrome.  
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As explained on section 1.4.2, progerin expression leads to a complex molecular and 
cellular response (Figure 5) that ultimately causes the HGPS phenotype. These progerin-
driven pathological features are not entirely restricted to telomere dysfunction and this 
could explain why telomeric ASOs do not contribute to ameliorate a subset of HGPS 
features, which is for instance the case of progerin-driven SASP expression (Figure 34). In 
fact, many of the cellular pathways misregulated in HGPS are highly interdependent, 
making challenging the identification of cellular features directly affected by progerin and 
driving HGPS etiology. Importantly, a major progerin-driven defect is the limited cellular 
proliferative capacity of the cell, which is notably improved upon telomeric ASO treatment 
(Figures 31, 36 and 40), which strongly places telomere dysfunction as a fundamental 
aspect in HGPS pathology. 
Overall, these observations confirm a direct role of tDDRNAs in progerin-driven telomere 
dysfunction, and that their inhibition results in the amelioration of the aging phenotype of 
progerin-expressing cultured cells and increases the lifespan in a HGPS mouse model. The 
use of telomeric ASOs opens the possibility for additional therapeutics as a potential 
treatment for HGPS patients alone or in combination with other drugs. 
Lastly, this telomeric ASO-based therapeutic strategy could potentially be extended to any 
genetic disease associated with telomere dysfunction and consequent DDR activation, such 
as dyskeratosis congenita, ataxia telangectasia, Werner syndrome, Bloom’s syndrome, 
Hoyeraal–Hreidarsson syndrome, Revesz syndrome and Coats plus syndrome (Armanios 
and Blackburn, 2012). 
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